Document:

Exhibit 10.01

 

SECURITIES PURCHASE AGREEMENT

 

This SECURITIES PURCHASE AGREEMENT (this “Agreement”)
is made and entered into as of April 8, 2016, by and between Amyris, Inc., a Delaware corporation (the “Company”),
and the Bill & Melinda Gates Foundation with headquarters at 500 Fifth Avenue North, Seattle, WA 98102 (the “Purchaser”).

 

Preliminary Statement

 

The Purchaser desires to purchase, and the Company
desires to offer and sell to the Purchaser, shares of the Company’s common stock, par value $0.0001 per share (“Common
Stock”).

 

Agreement

 

The parties, intending to be legally bound,
agree as follows:

 

ARTICLE
1

SALE OF SHARES

 

1.1Sale of Shares. Purchaser will,
in accordance with Section 2.2 hereof, purchase from the Company the number of shares of Common Stock, payable in cash, as set
forth next to Purchaser’s name on Schedule I hereto (such shares, the “Shares”) at a price per
share equal to US$1.14, which is the average of the daily closing price per share of Common Stock on the NASDAQ Stock Market for
the twenty (20) consecutive trading days ending on April 7, 2016. The total purchase price payable by Purchaser for the Shares
that Purchaser is hereby agreeing to purchase is set forth next to Purchaser’s name on Schedule I hereto (the “Aggregate
Purchase Price”).

 

ARTICLE
2

CLOSING; DELIVERY

 

2.1.           
Closing. The parties have entered into this Agreement via exchange of the requisite documents and signatures
on the date hereof, and the closing (“Closing”) of the transactions contemplated hereby shall take place within
five (5) business days following the date on which the last of the conditions set forth in Articles 5 and 6 have been satisfied
or waived in accordance with this Agreement (such date, the “Closing Date”), or at such other time as the Company
and the Purchaser mutually agree upon.

 

2.2.           
Payment. At the Closing, Purchaser shall pay the Company the applicable Aggregate Purchase Price by wire transfer
of immediately available funds to such account or accounts as the Company shall designate in writing to Purchaser at least five
(5) business days prior to the Closing Date.

 

2.3.           
Delivery. At the Closing, the Company
shall deliver to Purchaser, in addition to the other documents referenced in Article 6, a single stock certificate representing
the number of Shares purchased by Purchaser, as set forth next to Purchaser’s name on Schedule I hereto. Such

 

     

     

    

stock certificate shall be registered in the name
of Purchaser, or in such nominee’s or nominees’ name(s) as set forth next to Purchaser’s name on Schedule
I hereto, against payment of the Aggregate Purchase Price.

 

ARTICLE
3

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

The Company represents, warrants and covenants
to Purchaser, except as set forth in the disclosure letter supplied by the Company to the Purchaser dated as of the date hereof
(the “Disclosure Letter”), which exceptions shall be deemed to be part of the representations and warranties
made hereunder as provided therein, as follows:

 

3.1.           
Organization and Standing. The Company and each of its subsidiaries is duly incorporated, validly existing,
and in good standing under the laws of the jurisdiction of its organization. Each of the Company and its subsidiaries has all requisite
power and authority to own and operate its respective properties and assets and to carry on its respective business as presently
conducted and as proposed to be conducted. The Company and each of its subsidiaries is qualified to do business as a foreign entity
in every jurisdiction in which the failure to be so qualified would have, or would reasonably be expected to have, a material adverse
effect, individually or in the aggregate, upon the business, properties, tangible and intangible assets, liabilities, operations,
prospects, financial condition or results of operation of the Company and its subsidiaries or the ability of the Company or any
of its subsidiaries to perform their respective obligations under the Transaction Agreements (as defined below) (a “Material
Adverse Effect”).

 

3.2.           
Subsidiaries. As used in this Agreement, references to any “subsidiary” of a specified Person
shall refer to an Affiliate controlled by such Person directly, or indirectly through one or more intermediaries, as such terms
are used in and construed under Rule 405 under the Securities Act of 1933, as amended (the “Securities Act”)
(which, for the avoidance of doubt, shall include the Company’s controlled joint ventures, including shared-control joint
ventures). The Company’s subsidiaries, as of the date hereof, are listed on Exhibit 21.01 to the Company’s Annual Report
on Form 10-K for the year ended December 31, 2015 and, except for Novvi LLC, Total Amyris BioSolutions B.V. and as otherwise
Previously Disclosed (as defined in Section 3.9) are the only subsidiaries, direct or indirect, of the Company as of the date hereof.
All the issued and outstanding shares of each subsidiary’s capital stock have been duly authorized and validly issued, are
fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, were not issued in violation
of or subject to any preemptive rights or other rights to subscribe for or purchase securities, and, except as Previously Disclosed,
are owned by the Company or a Company subsidiary free and clear of all liens, encumbrances and equities and claims. As used herein,
“Person” shall mean any individual, corporation, limited liability company, partnership, joint venture, association,
joint-stock company, trust, unincorporated organization or government or any agency or political subdivision thereof, and an “Affiliate”
means, with respect to any Person, any other Person that directly or indirectly controls, is controlled by, or is under common
control with, such Person.

 

3.3.           
Power. The Company has all requisite power to execute and deliver this Agreement, to sell and issue the Shares
hereunder, and to carry out and perform its obligations under the terms of this Agreement, the Letter Agreement between the Company
and Purchaser

 

     

     

    

dated on or about the date of this Agreement (the
“Letter Agreement”) and any ancillary agreements and instruments to be entered into by the Company hereunder
(together, the “Transaction Agreements”).

 

3.4.           
Authorization. The execution, delivery, and performance of the Transaction Agreements by the Company has been
duly authorized by all requisite action on the part of the Company and its officers, directors and stockholders, and the Transaction
Agreements constitute the legal, valid, and binding obligations of the Company enforceable in accordance with their terms, except
(a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting
enforcement of creditors’ rights generally, and (b) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies (together, the “Enforceability Exceptions”).

 

3.5.           
Governmental Consents and Approvals. Except for any Current Report on Form 8-K or Notice of Exempt Offering
of Securities on Form D (a “Form D”) to be filed by the Company in connection with the transactions contemplated
hereby, the Company is not required to give any notice to, make any filing with, or obtain any authorization, consent, or approval
of any government or governmental agency in order to consummate the transactions contemplated by the Transaction Agreements. Assuming
the accuracy of each of the representations and warranties of Purchaser in Article 4 of this Agreement, no consent, approval,
authorization or other order of, or registration, qualification or filing with, any court, regulatory body, administrative agency,
self-regulatory organization, stock exchange or market (including The NASDAQ Stock Market), or other governmental body is required
for the execution and delivery of these Transaction Agreements, the valid issuance, sale and delivery of the Shares to be sold
pursuant to this Agreement other than such as have been made or obtained, or for any securities filings required to be made under
federal or state securities laws applicable to the offering of the Shares.

 

3.6.           
Non-Contravention. The execution and delivery of the Transaction Agreements, the issuance, sale and delivery
of the Shares to be sold by the Company under this Agreement, the performance by the Company of its obligations under the Transaction
Agreements and/or the consummation of the transactions contemplated thereby will not (a) conflict with, result in the breach
or violation of, or constitute (with or without the giving of notice or the passage of time or both) a violation of, or default
under, (i) any bond, debenture, note or other evidence of indebtedness, or under any lease, license, franchise, permit, indenture,
mortgage, deed of trust, loan agreement, joint venture or other agreement or instrument to which the Company or any subsidiary
is a party or by which it or its properties may be bound or affected, (ii) the Company’s Restated Certificate of Incorporation,
as amended and as in effect on the date hereof (the “Certificate of Incorporation”), the Company’s Bylaws,
as amended and as in effect on the date hereof (the “Bylaws”), or the equivalent document with respect to any
subsidiary, as amended and as in effect on the date hereof, or (iii) any statute or law, judgment, decree, rule, regulation,
ordinance or order of any court or governmental or regulatory body (including The NASDAQ Stock Market), governmental agency, arbitration
panel or authority applicable to the Company, any of its subsidiaries or their respective properties, except in the case of clauses
(i) and (iii) for such conflicts, breaches, violations or defaults that would not be likely to have, individually or in the
aggregate, a Material Adverse Effect, or (b) result in the creation or imposition of any lien, encumbrance, claim, security
interest or restriction whatsoever upon any of the material

 

     

     

    

properties or assets of the Company or any of
its subsidiaries or an acceleration of indebtedness pursuant to any obligation, agreement or condition contained in any material
bond, debenture, note or any other evidence of indebtedness or any material indenture, mortgage, deed of trust or any other agreement
or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is
bound or to which any of the property or assets of the Company is subject. For purposes of this Section 3.6, the term “material”
shall apply to agreements, understandings, instruments, contracts or proposed transactions to which the Company is a party or by
which it is bound involving obligations (contingent or otherwise) of, or payments to, the Company in excess of $100,000 in a consecutive
12-month period.

 

3.7.           
Shares. The Shares are duly authorized and when issued pursuant to the terms of this Agreement will be validly
issued, fully paid, and nonassessable, and will be free of any liens or encumbrances with respect to the issuance thereof; provided,
however, that the Shares shall be subject to restrictions on transfer under state or federal securities laws as set forth
in this Agreement, or as otherwise may be required under state or federal securities laws as set forth in this Agreement at the
time a transfer is proposed. The issuance and delivery of the Shares is not subject to preemptive, co-sale, right of first refusal
or any other similar rights of the stockholders of the Company or any other Person, or any liens or encumbrances and will not result
in the triggering of any anti-dilution or other similar rights under any outstanding securities of the Company.

 

3.8.           
No Registration. Assuming the accuracy of each of the representations and warranties of Purchaser herein,
the issuance by the Company of the Shares is exempt from registration under the Securities Act.

 

3.9.           
Reporting Status. The Company is subject to the reporting requirements of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), and has, in a timely manner, filed all documents and reports that the Company
was required to file under Section 13 of the Exchange Act during the twelve (12) months preceding the date of this Agreement (the
foregoing materials, together with any materials filed by the Company under the Exchange Act, whether or not required, collectively,
the “SEC Documents”). The SEC Documents complied as to form in all material respects with requirements of the
Securities Act and Exchange Act and the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”)
promulgated thereunder (collectively, the “SEC Rules”), and none of the SEC Documents and the information contained
therein, as of their respective filing dates, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under
which they were made, not misleading. As used in this Agreement, “Previously Disclosed” means information set
forth in or incorporated by reference into the SEC Documents filed with the SEC on or after March 30, 2016 but prior to the date
hereof (in each case, except for forward-looking information set forth in the “Risk Factors” section of the applicable
SEC Documents or in any forward-looking statement disclaimers and other statements that are similarly non-specific and are predictive
or forward-looking in nature).

 

3.10.       
Contracts. Each indenture, contract, lease, mortgage, deed of trust, note agreement, loan or other agreement
or instrument of a character that is required to be described or summarized in the SEC Documents or to be filed as an exhibit to
the SEC Documents under

 

     

     

    

the SEC Rules (collectively, the “Material
Contracts”) is so described, summarized or filed. The Material Contracts to which the Company or its subsidiaries are
a party have been duly and validly authorized, executed and delivered by the Company and constitute the legal, valid and binding
agreements of the Company or its subsidiaries, as applicable, enforceable by and against the Company or its subsidiaries, as applicable,
in accordance with their respective terms, subject to the Enforceability Exceptions.

 

3.11.       
Capitalization. As of the close of business on April 7, 2016, the authorized capital stock of the Company
consists of (a) 400,000,000 shares of Common Stock, $0.0001 par value per share, 208,080,851
shares of which are issued and outstanding, and (b) 5,000,000 shares of Preferred Stock, $0.0001 par value per share, of which
no shares are issued and outstanding. All subscriptions, warrants, options, convertible securities, and other rights (contingent
or other) to purchase or otherwise acquire equity securities of the Company issued and outstanding as of the date hereof, or material
contracts, commitments, understandings, or arrangements by which the Company or any of its subsidiaries is or may be obligated
to issue shares of capital stock, or securities or rights convertible or exchangeable for shares of capital stock, are as Previously
Disclosed. The issued and outstanding shares of the Company’s capital stock have been duly authorized and validly issued,
are fully paid and nonassessable, have been issued in compliance with all applicable federal and state securities laws, and were
not issued in violation of or subject to any preemptive rights or other rights to subscribe for or purchase securities. No holder
of the Company’s capital stock is entitled to preemptive or similar rights. There are no bonds, debentures, notes or other
indebtedness having general voting rights (or convertible into securities having such rights) of the Company issued and outstanding.
Except as Previously Disclosed, there are no agreements or arrangements under which the Company or any of its subsidiaries is obligated
to register the sale of any of their securities under the Securities Act. The Company has made available to the Purchaser, a true,
correct and complete copy of the Company’s Certificate of Incorporation and Bylaws.

 

3.12.       
Legal Proceedings. Except as Previously Disclosed, there is no action, suit or proceeding before any court,
governmental agency or body, domestic or foreign, now pending or, to the knowledge of the Company, threatened against the Company
or its subsidiaries wherein an unfavorable decision, ruling or finding would reasonably be expected to, individually or in the
aggregate, (i) materially adversely affect the validity or enforceability of, or the authority or ability of the Company to
perform its obligations under, this Agreement or (ii) have a Material Adverse Effect. The Company is not a party to or subject
to the provisions of any injunction, judgment, decree or order of any court, regulatory body, administrative agency or other governmental
agency or body that might have, individually or in the aggregate, a Material Adverse Effect.

 

3.13.       
No Violations. Neither the Company nor any of its subsidiaries is in violation of its respective certificate
of incorporation, bylaws or other organizational documents, or to its knowledge, is in violation of any statute or law, judgment,
decree, rule, regulation, ordinance or order of any court or governmental or regulatory body (including The NASDAQ Stock Market),
governmental agency, arbitration panel or authority applicable to the Company or any of its subsidiaries, which violation, individually
or in the aggregate, would be reasonably likely to have a Material Adverse Effect. Neither the Company nor any of its subsidiaries
is in default (and there exists no condition which, with or without the passage of time or giving of notice or both,

 

     

     

    

would constitute a default) in the performance
of any bond, debenture, note or any other evidence of indebtedness in any indenture, mortgage, deed of trust or any other material
agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries
is bound or by which the properties of the Company are bound, which would be reasonably likely to have a Material Adverse Effect.
There has not been, and to the knowledge of the Company, there is not pending or contemplated,
any investigation by the SEC involving the Company or any current or former director or officer of the Company and the Company
is not an “ineligible issuer” pursuant to Rules 164, 405 and 433 under the Securities Act. The Company has not received
any comment letter from the SEC relating to any SEC Documents which has not been finally resolved. The SEC has not issued
any stop order or other order suspending the effectiveness of any registration statement filed by the Company under the Exchange
Act or the Securities Act.

 

3.14.       
Governmental Permits; FDA Matters.

 

(a)Permits. The Company and its
subsidiaries possess all necessary franchises, licenses, certificates and other authorizations from any foreign, federal, state
or local government or governmental agency, department or body that are currently necessary for the operation of their respective
businesses as currently conducted, except where such failure to possess would not reasonably be expected to have, individually
or in the aggregate, a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received any notice of proceedings
relating to the revocation or modification of any such permit which, if the subject of an unfavorable decision, ruling or finding,
could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

 

(b)EPA and FDA Matters. As to each
of the manufacturing processes, intermediate products and research or commercial products of the Company and each of its subsidiaries,
including, without limitation, products or compounds currently under research and/or development by the Company, subject to the
jurisdiction of the United States Environmental Protection Agency (“EPA”) under the Toxic Substances Control
Act and regulations thereunder (“TSCA”) or the Food and Drug Administration (“FDA”) under
the Federal Food, Drug and Cosmetic Act and the regulations thereunder (“FDCA”) (each such product, a “Life
Science Product”), such Life Science Product is being researched, developed, manufactured, tested, distributed and/or
marketed in compliance in all material respects with all applicable requirements under the FDCA and TSCA and similar laws and regulations
applicable to such Life Science Product, including those relating to investigational use, premarket approval, good manufacturing
practices, labeling, advertising, record keeping, filing of reports and security. The Company has not received any notice or other
communication from the FDA, EPA or any other federal, state or foreign governmental entity (i) contesting the premarket approval
of, the uses of or the labeling and promotion of any Life Science Product or (ii) otherwise alleging any violation by the Company
of any law, regulation or other legal provision applicable to a Life Science Product. Neither the Company, nor any officer, employee
or agent of the Company has made an untrue statement of a material fact or fraudulent statement to the FDA or other federal, state
or foreign governmental entity performing similar or equivalent functions or failed to disclose a material fact required to be
disclosed to the FDA or such other federal, state or foreign governmental entity.

     

     

    

 

3.15.       
Listing Compliance. The Company is in compliance with the requirements of The NASDAQ Stock Market LLC (“The
NASDAQ Stock Market”) for continued listing of the Common Stock thereon and has no knowledge of any facts or circumstances
that could reasonably lead to delisting of its Common Stock from The NASDAQ Stock Market. The Company has taken no action designed
to, or likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or the listing of
the Common Stock on The NASDAQ Stock Market, nor has the Company received any notification that the SEC or The NASDAQ Stock Market
is contemplating terminating such registration or listing. The transactions contemplated by the Transaction Agreements will not
contravene the rules and regulations of The NASDAQ Stock Market. The Company will comply with all requirements of The NASDAQ Stock
Market with respect to the issuance of the Shares, including the filing of any listing notice with respect to the issuance of the
Shares.

 

3.16.       
Intellectual Property.

 

(a)Except as Previously Disclosed, the
Company and/or its subsidiaries owns or possesses, free and clear of all encumbrances, all legal rights to all intellectual property
and industrial property rights and rights in confidential information, including all (i) patents, patent applications, invention
disclosures, and all related continuations, continuations-in-part, divisional, reissues, re-examinations, substitutions and extensions
thereof, (ii) trademarks, trademark rights, service marks, service mark rights, corporate names, trade names, trade name rights,
domain names, logos, slogans, trade dress, design rights, and other similar designations of source or origin, together with the
goodwill symbolized by and of the foregoing, (iii) trade secrets and all other confidential information, ideas, know-how, inventions,
proprietary processes, formulae, models, and other methodologies, (iv) copyrights, (v) computer programs (whether in object code,
subject code or other form), algorithms, databases, compilations and data, technology supporting the foregoing, and all related
documentation, (vi) licenses to any of the foregoing, and (vii) all applications and registrations of the foregoing, and (viii)
all other similar proprietary rights (collectively, “Intellectual Property”) used or held for use in, or necessary
for the conduct of their businesses as now conducted and as proposed to be conducted, and neither the Company nor any of its subsidiaries
(1) has received any communications alleging that either the Company or any of its subsidiaries has violated, infringed or misappropriated
or, by conducting their businesses as now conducted and as proposed to be conducted, would violate, infringe or misappropriate
any of the Intellectual Property of any other Person, (2) knows of any basis for any claim that the Company or any of its subsidiaries
has violated, infringed or misappropriated, or, by conducting their businesses as now conducted and as proposed to be conducted,
would violate, infringe or misappropriate any of the Intellectual Property of any other Person, and (3) knows of any third-party
infringement, misappropriation or violation of any Company or any Company subsidiary’s Intellectual Property. The Company
has taken and takes reasonable security measures to protect the secrecy, confidentiality and value of its Intellectual Property,
including requiring all Persons with access thereto to enter into appropriate non-disclosure agreements. To the knowledge of the
Company, there has not been any disclosure of any material trade secret of the Company or a Company subsidiary (including any such
information of any other Person disclosed in confidence to the Company) to any other Person in a manner that has resulted or is
likely to result in the loss of trade secret in and to such information. Except as Previously Disclosed, and except as would not
reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, there are no outstanding

 

     

     

    

options, licenses or agreements, claims, encumbrances
or shared ownership interests of any kind relating to the Company’s or its subsidiaries’ Intellectual Property, nor
is the Company or its subsidiaries bound by or a party to any options, licenses or agreements of any kind with respect to the Intellectual
Property of any other Person.  

 

(b)To the Company’s knowledge, none
of the employees of the Company or its subsidiaries are obligated under any contract (including, without limitation, licenses,
covenants or commitments of any nature or contracts entered into with prior employers), or subject to any judgment, decree or order
of any court or administrative agency, that would interfere with the use of his or her best efforts to promote the interests of
the Company or its subsidiaries or would conflict with their businesses as now conducted and as proposed to be conducted. Neither
the execution nor delivery of the Transaction Agreements will conflict with or result in a breach of the terms, conditions or provisions
of, or constitute a default under any contract, covenant or instrument under which the Company or its subsidiaries or any of the
employees of the Company or its subsidiaries is now obligated, and neither the Company nor its subsidiaries will need to use any
inventions that any of its employees, or Persons it currently intends to employ, have made prior to their employment with the Company
or its subsidiaries, except for inventions that have been assigned or licensed to the Company or its subsidiaries as of the date
hereof. Each current and former employee or contractor of the Company or its subsidiaries that has developed any Intellectual Property
owned or purported to be owned by the Company or its subsidiaries has executed and delivered to the Company a valid and enforceable
Invention Assignment and Confidentiality Agreement that (i) assigns to the Company or such subsidiaries all right, title and interest
in and to any Intellectual Property rights arising from or developed or delivered to the Company or such subsidiaries in connection
with such Person’s work for or on behalf of the Company or such subsidiaries, and (ii) provides reasonable protection for
the trade secrets, know-how and other confidential information (1) of the Company or such subsidiaries and (2) of any third party
that has disclosed same to the Company or such subsidiaries. To the knowledge of the Company, no current or former employee, officer,
consultant or contractor is in default or breach of any term of any employment, consulting or contractor agreement, non-disclosure
agreement, assignment agreement, or similar agreement. Except as Previously Disclosed, to the knowledge of the Company, no present
or former employee, officer, consultant or contractor of the Company has any ownership, license or other right, title or interest,
directly or indirectly, in whole or in part, in any Intellectual Property that is owned or purported to be owned, in whole or part,
by the Company or its subsidiaries.

 

3.17.       
Financial Statements. The consolidated financial statements of the Company and its subsidiaries and the related
notes thereto included in the SEC Documents (the “Financial Statements”) comply in all material respects with
applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing
and present fairly, in all material respects, the financial position of the Company and its subsidiaries as of the dates indicated
and the results of its operations and cash flows for the periods therein specified subject, in the case of unaudited statements,
to normal year-end audit adjustments. Except as set forth in such Financial Statements (or the notes thereto), such Financial Statements
(including the related notes) have been prepared in accordance with U.S. generally accepted accounting principles applied on a
consistent basis throughout the periods therein specified (“GAAP”). Except as set forth in the Financial Statements,
neither the Company nor its subsidiaries has any material liabilities other than liabilities and obligations that have arisen in
the ordinary course of

 

     

     

    

business and which would not be required to be
reflected in financial statements prepared in accordance with GAAP.

 

3.18.       
Accountants. PricewaterhouseCoopers LLP, which will express its opinion with respect to the consolidated financial
statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, are registered
independent public accountants as required by the Exchange Act and the rules and regulations promulgated thereunder (and by the
rules of the Public Company Accounting Oversight Board).

 

3.19.       
Internal Accounting Controls. The Company maintains a system of internal accounting controls sufficient to
provide reasonable assurances that (i) transactions are executed in accordance with management’s general or specific
authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with
GAAP and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s
general or specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. The Company has disclosure controls and procedures (as
defined in Rules 13a-14 and 15d-14 under the Exchange Act) that are effective and designed to ensure that (1) information
required to be disclosed in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and
reported, within the time periods specified by the SEC Rules, and (2) such information is accumulated and communicated to the Company’s
management, including its principal executive officer and principal financial officer, to allow timely decisions regarding required
disclosure. The Company is otherwise in compliance in all material respects with all applicable provisions of the Sarbanes-Oxley
Act of 2002, as amended and the rules and regulations promulgated thereunder.

 

3.20.       
Off-Balance Sheet Arrangements. There is no transaction, arrangement or other relationship between the Company
or its subsidiaries and an unconsolidated or other off-balance sheet entity that is required to be disclosed by the Company in
its Exchange Act filings and is not so disclosed or that otherwise would be reasonably likely to have, individually or in the aggregate,
a Material Adverse Effect. There are no such transactions, arrangements or other relationships with the Company that may create
contingencies or liabilities that are not otherwise disclosed by the Company in its Exchange Act filings.

 

3.21.       
No Material Adverse Change. Except as set forth in the SEC Documents filed with the SEC on March 30, 2016,
since March 30, 2016:

 

(a) there has not been any event,
occurrence or development that, individually or in the aggregate, has had or that could reasonably be expected to result in a Material
Adverse Effect,

 

(b) the Company has not incurred
any liabilities (contingent or otherwise) other than (i) trade payables and accrued expenses incurred in the ordinary course of
business consistent with past practice and (ii) liabilities not required to be reflected in the Company's financial statements
pursuant to GAAP or not required to be disclosed in filings made with the SEC,

     

     

    

(c) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders
or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock other than routine withholding
in accordance with the Company’s existing stock-based plan,

 

(d)the Company has not altered its method
of accounting or the identity of its auditors, except as Previously Disclosed,

 

(e)the Company has not issued any equity
securities except pursuant to the Company’s existing stock based plans or as otherwise Previously Disclosed; and

 

(f)there has not been any loss or damage
(whether or not insured) to the physical property of the Company or any of its subsidiaries.

 

The Company is not as of the date hereof, and
after giving effect to the transactions contemplated hereby to occur at the Closing, will not be Insolvent (as defined below).
For purposes of this section, “Insolvent” means, with respect to any Person, such Person is unable to pay its
debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute and matured.

 

3.22.       
No Manipulation of Stock. Neither the Company nor any of its subsidiaries, nor to the Company’s knowledge,
any of their respective officers, directors, employees, Affiliates or controlling Persons has taken and will not, in violation
of applicable law, take, any action designed to or that might reasonably be expected to, directly or indirectly, cause or result
in stabilization or manipulation of the price of the Common Stock.

 

3.23.       
Insurance. The Company and its subsidiaries are insured by insurers of recognized financial responsibility
against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and its subsidiaries
are engaged. The Company and its subsidiaries will continue to maintain such insurance or substantially
similar insurance, which covers the same risks at the same levels as the existing
insurance with insurers which guarantee the same financial responsibility as the current insurers, and neither the Company nor
any subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage
expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant
increase in cost.

 

3.24.       
Properties. The Company and its subsidiaries have good and marketable title to all the properties and assets
(both tangible and intangible) described as owned by them in the consolidated financial statements included in the SEC Documents,
free and clear of all liens, mortgages, pledges, or encumbrances of any kind except (i) those, if any, reflected in such consolidated
financial statements (including the notes thereto), or (ii) those that are not material in amount and do not adversely affect
the use made and proposed to be made of such property by the Company or its subsidiaries. The Company and each of its subsidiaries
hold their leased properties under valid and binding leases. The Company and each of its subsidiaries own or lease all such properties
as are necessary to its operations as now conducted.

 

     

     

    

3.25.       
Tax Matters. The Company and its subsidiaries have filed all Tax Returns, and these Tax Returns are true,
correct, and complete in all material respects. The Company and each subsidiary (i) have paid all Taxes that are due from the Company
or such subsidiary for the periods covered by the Tax Returns or (ii) have duly and fully provided reserves adequate to pay all
Taxes in accordance with GAAP. No agreement as to indemnification for, contribution to, or payment of Taxes exists between the
Company or any subsidiary, on the one hand, and any other Person, on the other, including pursuant to any Tax sharing agreement,
lease agreement, purchase or sale agreement, partnership agreement or any other agreement not entered into in the ordinary course
of business. Neither the Company nor any of its subsidiaries has any liability for Taxes of any Person (other than the Company
or any of its subsidiaries) under Treasury Regulation Section 1.1502-6 (or any similar provision of any state, local or foreign
law), or as a transferee or successor, by contract or otherwise. Since the date of the Company's most recent Financial Statements,
the Company has not incurred any liability for Taxes other than in the ordinary course of business consistent with past practice.
Neither the Company nor its subsidiaries has been advised (a) that any of its Tax Returns have been or are being audited as of
the date hereof, or (b) of any deficiency in assessment or proposed judgment to its Taxes. Neither the Company nor any of its subsidiaries
has knowledge of any Tax liability to be imposed upon its properties or assets as of the date of this Agreement that is not adequately
provided for. The Company has not distributed stock of another corporation, or has had its stock distributed by another corporation,
in a transaction that was governed, or purported or intended to be governed, in whole or in part, by Section 355 of the Internal
Revenue Code (i) in the two years prior to the date of this Agreement or (ii) in a distribution that could otherwise constitute
part of a “plan” or “series of related transactions” (within the meaning of Section 355(e) of the Internal
Revenue Code) in conjunction with the purchase of the Shares. “Tax” or “Taxes” means any
foreign, federal, state or local income, gross receipts, license, payroll, employment, excise, severance, stamp, occupation, premium,
property, windfall, profits, environmental, customs, capital stock, franchise, employees’ income withholding, foreign or
domestic withholding, social security, unemployment, disability, real property, personal property, sales, use, transfer, value
added, alternative or add-on minimum or other similar tax, governmental fee, governmental assessment or governmental charge, including
any interest, penalties or additions to Taxes or additional amounts with respect to the foregoing. “Tax Returns”
means all returns, reports, or statements required to be filed with respect to any Tax (including any elections, notifications,
declarations, schedules or attachments thereto, and any amendment thereof) including any information return, claim for refund,
amended return or declaration of estimated Tax.

 

3.26.       
Investment Company Status. The Company is not, and immediately after receipt of payment for the Shares will
not be, an “investment company,” an “affiliated person” of, “promoter” for or “principal
underwriter” for, or an entity “controlled” by an “investment company,” within the meaning of the
Investment Company Act of 1940, as amended, or the rules and regulations promulgated thereunder.

 

3.27.       
Transactions With Affiliates and Employees. Except as Previously Disclosed, none of the officers or directors
of the Company or its subsidiaries and, to the knowledge of the Company, none of the employees of the Company or its subsidiaries
is presently a party to any transaction with the Company or any subsidiary (other than for services as employees, officers and
directors required to be disclosed under Item 404 of Regulation S-K under the Exchange Act.

 

     

     

    

3.28.       
Foreign Corrupt Practices. Neither the Company nor its subsidiaries or Affiliates, any director or officer,
nor to the knowledge of the Company, any agent, employee or other Person acting on behalf of the Company or its subsidiaries has,
in the course of its actions for, or on behalf of, the Company or any of its subsidiaries (a) used any corporate funds for
any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity, (b) made or promised
to make any direct or indirect unlawful payment to any foreign or domestic government official or employee (including any officer
or employee of a government or government-owned or controlled entity or of a public international organization, or any Person acting
in an official capacity for or on behalf of any of the foregoing, or of any political party or party official or candidate for
political office (each such Person, a “Government Official”)) from corporate funds, (c) violated or is
in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended or (d) made or promised to make
any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic Government
Official.

 

3.29.       
Money Laundering Laws. The operations of the Company and its subsidiaries are
and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency
and Foreign Transactions Reporting Act of 1970, as amended, and the Bank Secrecy Act, as amended by Title III of the Uniting and
Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (Title III of Pub.
L. 107-56 (signed into law on October 26, 2001)), applicable money laundering statutes and applicable rules and regulations thereunder
(collectively, the “Money Laundering Laws”), and no action, suit or proceeding by or before any court or governmental
agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering
Laws is pending or, to the Company’s knowledge, threatened. 

 

3.30.       
OFAC. Neither the Company, any director or officer, nor, to the Company’s
knowledge, any agent, employee, subsidiary or Affiliate of the Company is currently subject to any U.S. sanctions administered
by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”); and the Company will not directly
or indirectly use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary,
joint venture partner or other Person, for the purpose of financing the activities of any Person currently subject to any U.S.
sanctions administered by OFAC. 

 

3.31.       
Environmental Laws. The Company and its subsidiaries (i) are in compliance with any and all applicable
foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or
hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”), (ii) have received
all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses
and (iii) are in compliance with all terms and conditions of any such permit, license or approval, except where such noncompliance
with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and
conditions of such permits, licenses or approvals would not, singly or in the aggregate, have a Material Adverse Effect on the
Company and its subsidiaries, taken as a whole. There are no costs or liabilities associated with Environmental Laws (including,
without limitation, any capital or operating expenditures required for clean-up, closure of properties or compliance with Environmental
Laws or any permit, license or approval, any related constraints on operating

 

     

     

    

activities and any potential liabilities to third
parties) which would, singly or in the aggregate, have a Material Adverse Effect on the Company and its subsidiaries, taken as
a whole.

 

3.32.       
Employee Relations. Neither the Company nor any of its subsidiaries is a party to any collective bargaining
agreement or employs any member of a union. Neither the Company nor any of its subsidiaries is engaged in any unfair labor practice.
There is (i) (x) no unfair labor practice complaint pending or, to the Company’s knowledge, threatened against the Company
or any of its subsidiaries before the National Labor Relations Board, and no grievance or arbitration proceeding arising out of
or under collective bargaining agreements is pending or threatened, (y) no strike, labor dispute, slowdown or stoppage pending
or, to the Company’s knowledge, threatened against the Company or any of its subsidiaries and (z) no union representation
dispute currently existing concerning the employees of the Company or any of its subsidiaries, and (ii) to the Company’s
knowledge, (x) no union organizing activities are currently taking place concerning the employees of the Company or any of
its subsidiaries and (y) there has been no violation of any federal, state, local or foreign law relating to discrimination
in the hiring, promotion or pay of employees or any applicable wage or hour laws. No executive officer of the Company (as defined
in Rule 501(f) promulgated under the Securities Act) has notified the Company that such officer intends to leave the
Company or otherwise terminate such officer’s employment with the Company. No executive officer of the Company, to the knowledge
of the Company, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure
or proprietary information agreement, non-competition agreement, or any other agreement or any restrictive covenant, and the continued
employment of each such executive officer does not subject the Company or any of its subsidiaries to any liability with respect
to any of the foregoing matters.

 

3.33.       
ERISA. The Company and its subsidiaries are in compliance in all material respects with all presently applicable
provisions of the Employee Retirement Income Security Act of 1974, as amended, including the regulations and published interpretations
thereunder (herein called “ERISA”); no “reportable event” (as defined in ERISA) has occurred with
respect to any “pension plan” (as defined in ERISA) for which the Company or any of its subsidiaries would have any
liability; the Company has not incurred and does not expect to incur liability under (i) Title IV of ERISA with respect to
termination of, or withdrawal from, any “pension plan”; or (ii) Sections 412 or 4971 of the Internal Revenue Code
of 1986, as amended, including the regulations and published interpretations thereunder (the “Code”); and each
“Pension Plan” for which the Company would have liability that is intended to be qualified under Section 401(a) of
the Code is so qualified in all material respects and nothing has occurred, whether by action or by failure to act, which would
cause the loss of such qualification.

 

3.34.       
Obligations of Management. To the Company’s knowledge, each officer and key employee of the Company
or its subsidiaries is currently devoting substantially all of his or her business time to the conduct of the business of the Company
or its subsidiaries, respectively. The Company is not aware that any officer or key employee of the Company or its subsidiaries
is planning to work less than full time at the Company or its subsidiaries, respectively, in the future. To the Company’s
knowledge, no officer or key employee is currently working or plans to work for a competitive enterprise, whether or not such officer
or key employee is or will be compensated by such enterprise. To the Company’s knowledge, no officer or Person currently
nominated to become an officer of the Company or its subsidiaries is or has been subject to any

 

     

     

    

judgment or order of, and is not the subject of
any pending civil or administrative action by, the SEC or any self-regulatory organization.

 

3.35.       
Integration; Other Issuances of Shares. Neither the Company nor its subsidiaries or any Affiliates, nor any
Person acting on its or their behalf, has issued any shares of Common Stock or shares of any series of preferred stock or other
securities or instruments convertible into, exchangeable for or otherwise entitling the holder thereof to acquire shares of Common
Stock which would be integrated with the sale of the Shares to the Purchaser for purposes of the Securities Act or of any applicable
stockholder approval provisions, including, without limitation, under the rules and regulations of The NASDAQ Stock Market, nor
will the Company or its subsidiaries or Affiliates take any action or steps that would require registration of any of the Shares
under the Securities Act or cause the offering of the Shares to be integrated with other offerings if any such integration would
cause the issuance of the Shares hereunder to fail to be exempt from registration under the Securities Act as provided in Section
3.8 above or cause the transactions contemplated hereby to contravene the rules and regulations of The NASDAQ Stock Market.

 

3.36.       
No General Solicitation. Neither the Company nor its subsidiaries or any Affiliates, nor any Person acting
on its or their behalf, has offered or sold any of the Shares by any form of general solicitation or general advertising.

 

3.37.       
No Brokers’ Fees. The Company has not incurred any liability for any finder’s or broker’s
fee or agent’s commission in connection with the execution and delivery of this Agreement or the consummation of the transactions
contemplated hereby.

 

3.38.       
Registration Rights. The Company has not granted or agreed to grant to any person any rights (including “piggy-back”
registration rights) to have any securities of the Company registered with the SEC or any other governmental authority that have
not been satisfied or waived.

 

3.39.       
Application of Takeover Protections. There is no control share acquisition, business combination, poison pill
(including any distribution under a rights agreement) or other similar anti-takeover provision under the Company’s charter
documents or the laws of its state of incorporation that is or could become applicable to the Purchaser as a result of the Purchaser
and the Company fulfilling their obligations or exercising their rights under the Transaction Agreements, including, without limitation,
as a result of the Company’s issuance of the Shares and the Purchaser’s ownership of the Shares.

 

3.40.       
Disclosure. The Company understands and confirms that the Purchaser will rely on the foregoing representations
in effecting transactions in the Shares. All disclosure furnished by or on behalf of the Company to the Purchaser in connection
with this Agreement regarding the Company, its business and the transactions contemplated hereby is true and correct in all material
respects and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to
make the statements made therein, in light of the circumstances under which they were made, not misleading. The Company acknowledges
and agrees that Purchaser does not make and has not made any representations or warranties with respect to the transactions contemplated
hereby other than those set forth in Article 4 hereto.

 

     

     

    

ARTICLE
4

REPRESENTATIONS AND WARRANTIES OF THE PURCHASER

 

Purchaser represents, warrants and covenants to
the Company with respect to this purchase as follows:

 

4.1.           
Organization. The Purchaser is duly organized and validly existing under the laws of the jurisdiction of its
organization.

 

4.2.           
Power. The Purchaser has all requisite power to execute and deliver this Agreement and to carry out and perform
its obligations under the terms of this Agreement.

 

4.3.           
Authorization. The execution, delivery, and performance of this Agreement by the Purchaser has been duly authorized
by all requisite action, and this Agreement constitutes the legal, valid, and binding obligation of the Purchaser enforceable in
accordance with its terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws
of general application affecting enforcement of creditors’ rights generally, and (b) as limited by laws relating to the availability
of specific performance, injunctive relief or other equitable remedies.

 

4.4.           
Consents and Approvals. The Purchaser need not give any notice to, make any filing with, or obtain any authorization,
consent, or approval of any government or governmental agency in order to consummate the transactions contemplated by this Agreement.

 

4.5.           
Non-Contravention. Neither the execution and the delivery of this Agreement, nor the consummation of the transactions
contemplated hereby, will violate in any material respect any constitution, statute, regulation, rule, injunction, judgment, order,
decree, ruling, charge, or other restriction of any government, governmental agency, or court to which the Purchaser is subject.
No approval, waiver, or consent by the Purchaser under any instrument, contract, or agreement to which the Purchaser or any of
its Affiliates is a party is necessary to consummate the transactions contemplated hereby.

 

4.6.           
Purchase for Investment Only. The Purchaser is purchasing the Shares for the Purchaser’s own account
for investment purposes only and not with a view to, or for resale in connection with, any “distribution” in violation
of the Securities Act. By executing this Agreement, the Purchaser further represents that it does not have any contract, undertaking,
agreement, or arrangement with any Person to sell, transfer, or grant participation to such Person or to any third Person, with
respect to any of the Shares. The Purchaser understands that the Shares have not been registered under the Securities Act or any
applicable state securities laws by reason of a specific exemption therefrom that depends upon, among other things, the bona fide
nature of the investment intent as expressed herein.

 

4.7.           
Disclosure of Information. The Purchaser has had an opportunity to review the Company’s filings under
the Securities Act and the Exchange Act (including risk factors set forth therein), and the Purchaser represents that it has had
an opportunity to ask questions and receive answers from the Company to evaluate the financial risk inherent in making an investment
in the Shares. The Purchaser has not been offered the opportunity to purchase the Shares by means of any general solicitation
or general advertising.

 

     

     

    

4.8.           
Risk of Investment. The Purchaser realizes that the purchase of the Shares will be a highly speculative investment
and that the Purchaser may suffer a complete loss of its investment. The Purchaser understands all of the risks related to the
purchase of the Shares. By virtue of the Purchaser’s experience in evaluating and investing in private placement transactions
of securities in companies similar to the Company, the Purchaser is capable of evaluating the merits and risks of the Purchaser’s
investment in the Company and has the capacity to protect the Purchaser’s own interests.

 

4.9.           
Advisors. The Purchaser acknowledges that it has had the opportunity to review the Transaction Agreements
and the transactions contemplated thereby with the Purchaser’s own legal counsel.

 

4.10.       
Finder. The Purchaser is not obligated and will not be obligated to pay any broker commission, finders’
fee, success fee, or commission in connection with the transactions contemplated by this Agreement.

 

4.11.       
Restricted Shares. The Purchaser understands that the Company is under no obligation to register the Shares.
The Purchaser is aware that the Shares are “restricted securities” as defined in Rule 144 promulgated under the Securities
Act (“SEC Rule 144”). The Purchaser is aware that SEC Rule 144 permits limited resales of securities purchased
in a private placement subject to the satisfaction of certain conditions.

 

4.12.       
Legend. It is understood by the Purchaser that each certificate representing the Shares shall be endorsed
with a legend substantially in the following form:

 

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY
NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT
FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED
BY THE HOLDER), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS
SOLD PURSUANT TO RULE 144 UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THESE SECURITIES
MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.”

 

Subject to Section 7.3, the Company need not register
a transfer of Shares unless the conditions specified in the foregoing legend are satisfied. Subject to Section 7.3, the Company
may also instruct its transfer agent not to register the transfer of any of the Shares unless the conditions specified in the foregoing
legend are satisfied.

 

     

     

    

4.13.       
Investor Qualification. The Purchaser is an “accredited investor” as defined in Rule 501(a) of
Regulation D under the Securities Act. The Purchaser agrees to furnish any additional information that the Company deems reasonably
necessary in order to verify such Purchaser’s status as an “accredited investor.”

 

ARTICLE
5

CONDITIONS TO COMPANY’S OBLIGATIONS AT THE CLOSING.

 

The Company’s obligation to complete the
sale and issuance of the Shares and deliver the Shares to Purchaser at the Closing shall be subject to the following conditions
to the extent not waived by the Company:

 

(a) Receipt of Payment. The Company
shall have received payment by wire transfer of immediately available funds as provided in Article 2 hereof in the full amount
of the Aggregate Purchase Price for the number of Shares being purchased by Purchaser at the Closing as set forth next to Purchaser’s
name on Schedule I hereto.

 

(b) Representations and Warranties.
The representations and warranties made by Purchaser in Section 4 hereof shall be true and correct in all material respects
as of, and as if made on, the date of this Agreement and as of the Closing.

 

(c) Receipt of Executed Documents.
Purchaser shall have duly executed and delivered to the Company this Agreement.

 

ARTICLE
6

CONDITIONS TO PURCHASER’S OBLIGATIONS AT THE CLOSING

 

Purchaser’s obligation to accept delivery
of the Shares and to pay for the Shares shall be subject to the following conditions to the extent not waived by Purchaser:

 

(a)Delivery. As described in Section
2.3, the Company shall provide Purchaser with a single stock certificate representing the number of Shares purchased by Purchaser
hereunder.

 

(b)Representations and Warranties.
The representations and warranties made by the Company in Article 3 hereof shall be true and correct in all respects as of,
and as if made on, the date of this Agreement and shall be true and correct in all material respects as of, and as if made on,
the Closing.

 

(c)Performance. The Company shall
have performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement and the Letter
Agreement that are required to be performed or complied with by the Company on or before the Closing.

 

(d)Legal Opinion. Purchaser shall
have received an opinion of Fenwick & West LLP, counsel to the Company, in a form reasonably acceptable to Purchaser.

 

(e)Certificate. Purchaser shall have
received a certificate signed by the Company’s Chief Executive Officer and Chief Financial Officer to the effect that (i)
the representations and

 

     

     

    

warranties of the Company in Article 3 hereof are true and correct in all respects
as of, and as if made on, the date of this Agreement and are true and correct in all material respects as of the Closing, and (ii)
the Company has satisfied in all material respects all of the conditions set forth in this Agreement.

 

(f)Good Standing. The Company is
validly existing as a corporation in good standing under the laws of Delaware as evidenced by a certificate of the Secretary of
State of the State of Delaware, a copy of which was provided to Purchaser.

 

(g)Secretary’s Certificate.
Purchaser shall have received a certificate, executed by the Secretary of the Company and dated as of the Closing Date, as to (i)
the resolutions approving the issuance of the Shares as adopted by the Company’s Board of Directors in a form reasonably
acceptable to Purchaser, (ii) the certificate of incorporation, and (iii) the bylaws, each as in effect as of the Closing Date.

 

(h)Board Approval. The terms and
conditions of the issuance of the Shares and the Transaction Agreements shall have been approved by the Company’s Board of
Directors.

 

(i)Approvals. The Company shall have
obtained all governmental, regulatory or third party consents and approvals, third party waivers (or applicable third party elections),
if any, necessary for the sale of the Shares.

 

(j)Receipt of Executed Documents.
The Company shall have duly executed and delivered to Purchaser this Agreement and the Letter Agreement.

 

(k)Tax Opinion. Purchaser will have
obtained a written legal opinion from tax counsel (to be provided at Purchaser’s expense) that the purchase of the Shares
pursuant to this Agreement will qualify as a program-related investment under the Code.

 

(l)Amendment of Exclusive License and
Termination of Non-Compete with The Institute for OneWorld Health. The Institute for OneWorld Health (or its successor organization)
(“IOWH”) shall have (i) modified to non-exclusive or terminated, in writing, the exclusive license and sublicense
granted by the Company to IOWH, per their Amended and Restated Exclusive Development and Commercialization Agreement dated January
11, 2008 (the “IOWH Agreement”), under certain patents and patent applications and (ii) waived or terminated,
in writing, the Company’s non-compete covenant in Section 7.6(a) of the IOWH Agreement, in each case in a form acceptable
to Purchaser and to the Company, in their respective discretion.

 

 

ARTICLE
7

OTHER AGREEMENTS OF THE PARTIES

 

7.1.           
Securities Laws Disclosure; Publicity. On or before 5:30 p.m., U.S. Eastern Time, on the fourth trading day
immediately following the execution of this Agreement, the Company will file a Current Report on Form 8-K with the SEC describing
the terms of the material Transaction Agreements.

 

     

     

    

7.2.           
Form D. The Company agrees to timely file a Form D with respect to the Shares as required under
Regulation D and to provide a copy thereof to the Purchaser (provided that the posting of the Form D on the SEC’s EDGAR
system shall be deemed delivery of the Form D for purposes of this Agreement).

 

7.3.           
Removal of Legend and Transfer Restrictions. The Company hereby covenants with the Purchaser to, no later
than three trading days following the delivery by the Purchaser to the Company of a legended certificate representing Shares (endorsed
or with stock powers attached, signatures guaranteed, and otherwise in form necessary to affect the reissuance and/or transfer),
in preparation for a present or future transfer or sale of all or a portion of the Shares pursuant to (1) an effective registration
statement that is effective at the time of such sale or transfer, (2) a transaction exempt from the registration requirements of
the Securities Act in which the Company receives an opinion of counsel reasonably satisfactory to the Company that the Shares are
freely transferable and that the legend is no longer required on such stock certificate, or (3) an exemption from registration
pursuant to SEC Rule 144, provided such Shares are, at the time of such delivery, permitted to be so transferred or sold under
the Securities Act and regulations promulgated thereunder (as determined by legal counsel to the Company), deliver or cause the
Company’s transfer agent to deliver to the transferee of the Shares or to the Purchaser, as applicable, a new stock certificate
representing such Shares that is free from all restrictive and other legends. The Company acknowledges that the remedy at law for
a breach of its obligations under this Section 7.3 may be inadequate and agrees, in the event of a breach or threatened breach
by the Company of the provisions of this Section 7.3 with respect to Purchaser, the Purchaser shall be entitled, in addition
to all other available remedies, to an order and/or injunction restraining any breach and requiring immediate issuance and transfer,
without the necessity of showing economic loss and without any bond or other security being required.

 

7.4.           
Use of Proceeds. The Company agrees to use the proceeds of the offering in accordance with the Letter Agreement.

 

7.5.           
Subsequent Equity Sales. The Company shall not, and shall use its commercially reasonable efforts to ensure
that no Affiliate of the Company shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any
security (as defined in Section 2 of the Securities Act) that will be integrated with the offer or sale of the Shares in a manner
that would require the registration under the Securities Act of the sale of the Shares to the Purchaser, or that will be integrated
with the offer or sale of the Shares for purposes of the rules and regulations of any trading market such that it would require
stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing
of such subsequent transaction.

 

7.6.           
Listing. The Company shall promptly take any action required to maintain the listing of all of the Shares,
once they have been issued, upon each national securities exchange and automated quotation system, if any, upon which shares of
Common Stock are then listed (subject to official notice of issuance) and shall maintain, so long as any other shares of Common
Stock shall be so listed, such listing of all Shares from time to time issuable under the terms of the Transaction Agreements.
The Company shall take all actions within its control to comply with the reporting requirements of the Exchange Act and each applicable
national securities

 

     

     

    

exchange and automated quotation system on which the Common Stock
is listed. The Company shall make and keep public information available, as those terms are understood and defined in SEC Rule
144, for so long as required in order to permit the resale of the Shares pursuant to SEC Rule 144 and to file periodic reports
with the SEC whether or not required to do so. The Company shall not take any action which would be reasonably expected to result
in the delisting or suspension of the Common Stock on The NASDAQ Stock Market.

 

7.7.           
Corporate Existence. The Company will do or cause to be done all things necessary to preserve and keep in
full force and effect its corporate existence in accordance with its organizational documents.

 

7.8.           
Taxes. The Company shall pay prior to delinquency all taxes, assessments and governmental levies, except as
contested in good faith and by appropriate proceedings.

 

 

ARTICLE
8

MISCELLANEOUS

 

8.1.           
Survival. The representations, warranties and covenants contained herein shall survive the execution and delivery
of this Agreement and the sale of the Shares.

 

8.2.           
Indemnification.

 

(a)Indemnification of Purchaser.
The Company agrees to indemnify and hold harmless Purchaser and its Affiliates and their respective directors, officers, trustees,
members, managers, employees and agents, and their respective successors and assigns, from and against any and all losses, claims,
damages, liabilities and expenses (including without limitation reasonable attorney fees and disbursements and other expenses reasonably
incurred in connection with investigating, preparing or defending any action, claim or proceeding, pending or threatened and the
costs of enforcement thereof) (collectively, “Losses”) to which such Person may become subject as a result of
any breach of representation, warranty, covenant or agreement made by or to be performed on the part of the Company under this
Agreement, and will reimburse any such Person for all such Losses as they are incurred by such Person.

 

(b)Conduct of Indemnification Proceedings.
Any Person entitled to indemnification hereunder shall (i) give prompt notice to the Company of any claim with respect to which
it seeks indemnification and (ii) permit the Company to assume the defense of such claim with counsel reasonably satisfactory to
the indemnified party; provided that any Person entitled to indemnification hereunder shall have the right to employ separate
counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such
Person unless (a) the Company has agreed to pay such fees or expenses, or (b) the Company shall have failed to assume the defense
of such claim and employ counsel reasonably satisfactory to such Person or (c) in the reasonable judgment of any such Person, based
upon written advice of its counsel, a conflict of interest exists between such Person and the Company with respect to such claims
(in which case, if the Person notifies the Company in writing that such Person elects to employ separate counsel at the expense
of the Company, the Company shall not have the right to assume the defense of such claim on behalf of such Person);

 

     

     

    

and provided, further, that the failure of any indemnified
party to give notice as provided herein shall not relieve the Company of its obligations hereunder, except to the extent that such
failure to give notice shall materially adversely affect the Company in the defense of any such claim or litigation. It is understood
that the Company shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more
than one separate firm of attorneys at any time for all such indemnified parties. The Company will not, except with the consent
of the indemnified party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment
or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to
such indemnified party of a release from all liability in respect of such claim or litigation. No indemnified party will, except
with the consent of the Company, consent to entry of any judgment or enter into any settlement.

 

8.3.           
Assignment; Successors and Assigns. This Agreement may not be assigned by either party without the prior written
consent of the other party; provided, that this Agreement may be assigned by Purchaser to (i) any successor charitable organization
of Purchaser from time-to-time that is a tax exempt organization as described in Section 50l(c)(3) of the Code or (ii) any tax
exempt organization as described in Section 50l(c)(3) of the Code controlled by one or more trustees of Purchaser, in each case
to whom Purchaser validly transfers any Common Stock purchased hereunder. Purchaser will notify the Company of any such assignment,
including the identity of the assignee, in a timely manner. This Agreement and all provisions thereof shall be binding upon, inure
to the benefit of, and are enforceable by the parties hereto and their respective successors and permitted assigns.

 

8.4.           
Notices. All notices, requests, and other communications hereunder shall be in writing and will be deemed
to have been duly given and received (a) when personally delivered, (b) when sent by facsimile upon confirmation of receipt,
(c) one business day after the day on which the same has been delivered prepaid to a nationally recognized courier service,
or (d) five business days after the deposit in the United States mail, registered or certified, return receipt requested,
postage prepaid, in each case addressed to, as to the Company, Amyris, Inc., 5885 Hollis Street, Suite 100, Emeryville, CA 94608,
Attn: General Counsel, facsimile number: , with a copy to Fenwick & West LLP, 801 California Street, Mountain View, CA 94041,
Attn: Dan Winnike, Esq., facsimile number: , and as to the Purchaser at the address and facsimile number set forth below the Purchaser’s
signature on the signature pages of this Agreement. Any party hereto from time to time may change its address, facsimile number,
or other information for the purpose of notices to that party by giving notice specifying such change to the other parties hereto.
Purchaser and the Company may each agree in writing to accept notices and other communications to it hereunder by electronic communications
pursuant to procedures reasonably approved by it; provided that approval of such procedures may be limited to particular notices
or communications.

 

8.5.           
Governing Law; Jurisdiction. This Agreement, and the provisions, rights, obligations, and conditions set forth
herein, and the legal relations between the parties hereto, including all disputes and claims, whether arising in contract, tort,
or under statute, shall be governed by and construed in accordance with the laws of the State of New York without giving effect
to its conflict of law provisions. Any and all disputes arising out of, or in connection with, the interpretation, performance,
or nonperformance of this Agreement, and any and all disputes arising out of, or in connection with, transactions related to this
Agreement, shall be litigated

 

     

     

    

solely and exclusively before the U.S. District Court for the Southern
District of New York. The parties consent to the in personam jurisdiction of said court for the purposes of any such litigation
and waive, fully and completely, any right to dismiss and/or transfer any action pursuant to 28 U.S.C. § 1404 or 1406 (or
any successor statute). In the event the U.S. District Court for the Southern District of New York does not have subject matter
jurisdiction of such matter, then such matter shall be litigated solely and exclusively before the appropriate state court of competent
jurisdiction located in the state of New York.

 

8.6.           
Severability. In the event that any provision of this Agreement or the application of any provision hereof
is declared to be illegal, invalid, or otherwise unenforceable by a court of competent jurisdiction, the remainder of this Agreement
shall not be affected except to the extent necessary to delete such illegal, invalid, or unenforceable provision unless that provision
held invalid shall substantially impair the benefits of the remaining portions of this Agreement.

 

8.7.           
Confidentiality. This Agreement and its terms are considered “Proprietary Information” of each
party under the parties’ Mutual Confidential Disclosure Agreement dated June 8, 2015 (the “CDA”), subject
to the obligations and exceptions in the CDA.

 

8.8.           
Headings. The headings in this Agreement are for convenience of reference only and shall not constitute a
part of this Agreement, nor shall they affect its meaning, construction, or effect.

 

8.9.           
Entire Agreement. This Agreement, the Letter Agreement, and the CDA embody the entire understanding and agreement
between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings relating
to the subject matter hereof.

 

8.10.       
Finder’s Fee. The Company agrees that it shall be responsible for the payment of any placement agent’s
fees, financial advisory fees, or brokers’ commissions (other than for Persons engaged by Purchaser) relating to or arising
out of the transactions contemplated hereby. The Company shall pay, and hold Purchaser harmless against, any liability, loss or
expense (including, without limitation, attorney’s fees and out-of-pocket expenses) arising in connection with any claim
for any such fees or commissions.

 

8.11.       
Expenses. Each party will bear its own costs and expenses in connection with this Agreement.

 

8.12.       
Further Assurances. The parties agree to execute and deliver all such further documents, agreements and instruments
and take such other and further action as may be necessary or appropriate to carry out the purposes and intent of this Agreement.

 

8.13.       
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall constitute an
original, but all of which, when taken together, shall constitute but one instrument, and shall become effective when one or more
counterparts have been signed by each party hereto and delivered to the other party. Facsimile signatures shall be deemed originals
for all purposes hereunder.

 

[Signature page follows]

 

 

 

 

     

     

    

 

This Securities Purchase Agreement is hereby confirmed and accepted
by the Company as of April 8, 2016.

 

	 	AMYRIS, INC.
	 	 	 
	 	By:	/s/ Nicholas Khadder	 
	 	Name:	Nicholas Khadder	 
	 	Title:	Corporate Secretary & General Counsel	 
	 	 	 	 
	 	PURCHASER:	 
	 	 	 	 
	 	BILL & MELINDA GATES FOUNDATION
	 	 	 	 
	 	By:	/s/ Jim Bromley	 
	 	 	 	 
	 	Name:	Jim Bromley	 
	 	 	 	 
	 	Title:	CFO	 

 

	 	Address: 	 	 
	 	 	 	 
	 	500 Fifth Avenue North	 
	 	Seattle, WA 98102
	 	 	 	 
	 	Facsimile No.	 	 
	 	Email Address:	 	 

 

 

 

 

 

 

 

     

     

    

 

Schedule I

 

 

Schedule of Purchasers

 

 

 

	Purchaser	 	Maximum Amount of Purchase	 	Price per Share (per Section 1.1)	 	Number of Shares Purchased	 	Aggregate Purchase Price
	Bill & Melinda Gates Foundation	 	US$5,000,000	 	 	 US$1.14
	 	 	 	4,385,964	 	 	 	US$4,999,998.96Exhibit 10.02

 

 

CONFIDENTIAL

 

April 8, 2016

 

Amyris, Inc.

5885 Hollis Street, St. 100

Emeryville, CA 94608

Attention: Chief Executive Officer

 

Re: Transaction Documents between the Bill & Melinda Gates Foundation and Amyris,
Inc.

 

Ladies and Gentleman:

 

This letter agreement (including all appendices
and attachments hereto, the “Letter Agreement”) is entered into as of the date first set forth above in connection
with the investment by the Bill & Melinda Gates Foundation (the “Foundation”), a Washington charitable trust
that is a tax-exempt private foundation, of five million dollars ($5,000,000.00) (the “Foundation Investment”)
in common stock, par value $0.0001 per share of Amyris, Inc. (the “Company”). The Foundation has agreed to make
the Foundation Investment in accordance with and subject to the provisions of the Stock Purchase Agreement dated April 8, 2016
(“SPA”), and the Mutual Confidential Disclosure Agreement dated June 8, 2015 (the “CDA”)
(collectively, as amended from time to time in accordance with their terms, the “Transaction Documents”).

 

In consideration of the Foundation entering
into the SPA and making the Foundation Investment on the terms and conditions stated herein and in the Transaction Documents, and
for other good and valuable consideration, the undersigned hereby irrevocably agree as follows:

 

1.                 
Charitable Purposes and Use of Funds

 

(a)               
The Foundation is making the Foundation Investment as a “program-related investment” within the meaning
of Section 4944(c) of the U.S. Internal Revenue Code (the “Code”). The Foundation’s primary purpose in
making the Foundation Investment is to further significantly the accomplishment of the Foundation’s charitable purposes,
including the relief of the poor, distressed, and underprivileged, the advancement of science, and the promotion of health, by
seeking to (i) address global health challenges that disproportionately impact developing countries and (ii) increase the access
of poor and distressed individuals and families in developing countries to life-saving and other important vaccines, drugs and
technologies that may assist in the prevention, treatment and detection of diseases or conditions within the Foundation’s
priority areas (collectively, the “Charitable Purposes”).

 

(b)              
The Foundation believes that the Company’s technology and development expertise have the potential to produce
quality supplies of artemisinic acid (“AA”) and amorphadiene (“AD”) that may be converted
to artemisinin for inclusion in artemisinin combination therapies used to treat malaria (“ACTs”) in furtherance
of the Charitable Purposes to ensure a more stable supply of ACTs, interrupting a trend of volatile agricultural artemisinin supply
that results in price uncertainty and periods of very high artemisinin cost. The Foundation is entering into this transaction to
(i) reduce supply uncertainty of artemisinin by increasing the

 

    	 	2	 

     

    

supplier base for AA and AD through the entry
and continued operation of the Company as a reliable, quality and affordable supplier of AA and AD for conversion into artemisinin
and then for inclusion in quality-assured ACTs and (ii) lower the cost of artemisinin via lower-cost AA and AD with the potential
reduction in cost of ACTs through the Company’s production of AA and AD at lower costs than other alternative production
methods.

 

(c)               
The Company agrees to use the aggregate amount of the proceeds from the Foundation Investment solely to develop a
new, low-cost Strain (including Strain improvements, process development, manufacturing, and quality systems) to produce AA and
AD from the Strain and supply such AA and AD, at prices lower than AA and AD are supplied as of the date of this Letter Agreement,
to companies qualified to convert AA or AD to artemisinin for anti-malarial uses and/or that produce ACTs that meet applicable
WHO standards (collectively, “Purchasers”) in accordance with the Global Access Commitments below. For clarity,
notwithstanding anything in this Agreement or any other Transaction Document to the contrary, the Company is not required to segregate
the proceeds of the Foundation Investment from other Company funds, but the Company will instead track and report, per Section
7, its expenditures related to its Global Access Commitments, which, in the aggregate, will be no less than the amount of the Foundation
Investment.

 

2.                 
Definitions. For the purposes of this Letter Agreement, the following terms have the meanings indicated.
Other terms are defined elsewhere in this Letter Agreement.

 

“Affiliate” means any person
or entity that, directly or indirectly, controls, is controlled by or is under common control with a party to this Letter Agreement
for so long as such control exists, where “control” (for purposes of this definition of “Affiliate” only)
means having the decision-making authority as to such person or entity and, further, where such control shall be presumed to exist
where a person or entity owns more than fifty percent (50%) of the equity (or such lesser percentage which is the maximum allowed
to be owned by a foreign corporation in a particular jurisdiction) entitled to vote regarding composition of the board of directors
or other body entitled to direct the affairs of the entity. For the avoidance of doubt, an Affiliate of the Foundation includes
(a) any successor charitable organization of the Foundation from time to time that is a tax-exempt organization as described in
Section 50l(c)(3) of the Code and (b) any tax exempt organization as described in Section 50l(c)(3) of the Code controlled by one
or more trustees of the Foundation.

 

“Change in Control” means (i) the acquisition
after the date of this Letter Agreement, directly or indirectly, by any person or group (within the meaning of section 13(d)(3)
of Exchange Act) of the beneficial ownership of securities of the Company possessing more than 50% of the total combined voting
power of all outstanding voting securities of the Company; (ii) a merger, consolidation or other similar transaction involving
the Company, except for a transaction in which the holders of the outstanding voting securities of the Company immediately prior
to such merger, consolidation or other transaction hold, in the aggregate, securities possessing more than 50% of the total combined
voting power of all outstanding voting securities of the surviving entity immediately after such merger, consolidation or other
transaction; or (c) the sale, transfer or other disposition (in one transaction or a series of related transactions) of all or
substantially all of the assets of the Company.

 

    	 	3	 

     

    

“Commitment Period” means the period beginning
on the Closing Date (as defined in the SPA) and ending on the earliest to occur of (i) the later of such time as ACTs are no longer
the WHO’s recommended first line treatment for malaria or the Foundation no longer owns any Foundation Stock, and (ii) such
time as both the Company’s Strain development program under this Letter Agreement has concluded (the Company has incurred
expenditures related to its Global Access Commitments which, in the aggregate, are equal to or greater than the Foundation Investment)
and the Foundation has sublicensed, under Section 3(d)(ii), at least three (3) sublicensees to make AA or AD from the Escrowed
Materials and any two (2) of these sublicensees Comes to Market.

 

“Common Stock” means shares
of the Company’s common stock, par value $0.0001 per share and any securities issued as a dividend or other distribution
with respect to, or in exchange for or in replacement of, such common stock.

 

“COGS” means Amyris’s
standard cost of production of AA or AD, as determined in accordance with Amyris’s usual and customary accounting methods,
which are in accordance with GAAP; provided that this amount is not greater than the “total cost of ownership” as determined
by the Foundation’s methodology in the Total Cost of Ownership Handbook for Pharmaceuticals.

 

“Comes to Market” means the
sublicensee commences commercial launch of AA or AD that meets applicable WHO standards, as demonstrated by a purchase of such
AA or AD by a Purchaser, which purchase is confirmed by the Foundation in its discretion.

 

“Exchange Act” means the Securities
Exchange Act of 1934, as amended.

 

“Fair Market Value” of the
Foundation Stock means (a) if the Common Stock is Freely Tradable, the closing price of the Common Stock on the primary U.S. securities
exchange on which the stock trades on the most recent day such exchange was open for trading prior to the closing date of the redemption
or purchase under Section 6(b) below and (b) if the Common Stock is not Freely Tradable, the then current fair market value per
share of the Foundation Stock as determined by a mutually agreed upon (which agreement will not be unreasonably withheld, conditioned
or delayed) third-party appraiser.

 

“Freely Tradable” means that
the Common Stock is a class of securities registered under section 12 (or any successor provision) of the Exchange Act, is not
subject to restrictions from trading under the Securities Act or state securities laws and is listed on a U.S. national securities
exchange and the Company is current in its filings with the SEC.

 

“Foundation Stock” means all
shares of Common Stock purchased by the Foundation under the SPA and held by the Foundation or its Affiliates.

 

“Intellectual Property” means all (a) technology
and (b) intellectual property rights, privileges and priorities provided under federal, state, foreign and multinational law,
including all: (i) patents and patent applications, inventions, discoveries, machines, manufactures, tangible compositions of matter,
devices, articles of manufacture, assays, biological, chemical or physical materials and other similar materials, compositions
of matter, processes, formulae, designs, methods, techniques, procedures, concepts, developments, technology, and Know-How, whether
patented or patentable;

 

    	 	4	 

     

    

(ii) copyrights and works of authorship, including computer applications,
software, files, databases, documentation, reports and regulatory submissions; and (iii) trade secrets, drawings, lists and other
proprietary, non-public or confidential information, documents or materials in any media.

 

“Know-How” means all technical information, processes,
procedures, compositions, devices, methods, formulae, protocols, techniques, software, designs, drawings, reports or data.

 

“Material Contract” means any
contract of the Company that has been filed or was required to have been filed with the SEC pursuant to Item 601(b)(4) or Item
601(b)(10) of Regulation S-K.

 

“Minimum Purchase Price” means a price per share
of the Foundation Stock equal to the price per share paid by the Foundation for the Foundation Stock pursuant to the SPA(as adjusted
for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof),
plus a compounded annual return of 10% per annum from the date of issuance of the Foundation Stock until the date the Foundation
has received payment in full for the Foundation Stock pursuant to the Withdrawal Rights in Section 6(b).

 

“SEC” means the U.S. Securities
and Exchange Commission.

 

“Securities Act” means the
Securities Act of 1933, as amended.

 

“Strain” means a yeast genetically
engineered, developed, or enhanced by the Company to produce AA or AD. For clarity, “Strain” encompasses populations,
subpopulations, and derivatives of such genetically engineered, developed, or enhanced yeast.

 

“Target Diseases” means polio, malaria (including
falciparum and vivax), tuberculosis, cryptococcus, certain neglected infectious diseases (including hookworm, trichuris, ascaris,
loa, leishmaniasis, trypanosomiasis, chagas, rabies, cysticercosis, trachoma, onchocerciasis, schistosorniasis, Japanese encephalitis,
guinea worm, lymphatic filariasis, human African trypanosomiasis (HAT) and leprosy), pertussis, measles, rubella, yellow fever,
Group B streptococcus, dengue, zika, Ebola, Lassa Fever, and diarrhea/enteric diseases (including ETEC, shigella, cryptosporidium,
cholera, typhoid, rotavirus, norovirus and hepatitis E).

 

“Technical Assistance”
means providing, with up to five personnel, up to a maximum of one-hundred twenty (120) hours
per person per month, teleconference, video conference, and/or in-person consultation services by relevant Company employees with
regard to the sublicensee’s implementation of the Escrowed Materials to produce AA or AD from the escrowed Strain solely
for conversion into artemisinin that is only included in ACTs used to treat malaria. All such hours provided will be billed to
the Foundation or sublicensee at an hourly rate of US$168 per hour. The project plan for Technical Assistance, including staffing
levels, will be mutually agreed by the Company and the Foundation or sublicensee in advance of the commencement of such services.
The Company will invoice the Foundation or sublicensee at the end of each month for the hours of Technical Assistance provided
during such just-ended month, and the Foundation or sublicensee will pay such invoiced amount to the Company within thirty (30)
days after receipt of the invoice. The Foundation or sublicensee shall also reimburse the
Company its reasonable documented expenses, including travel expenses, incurred with respect to the Technical Assistance, and such

 

    	 	5	 

     

    

amounts will be included in the invoiced amounts. For clarity, if
neither the Foundation nor the sublicensee has timely paid an invoice for Technical Assistance, the parties agree that the Company
has no obligation to provide Technical Assistance to such sublicensee until the outstanding invoice has been paid.

 

“WHO” means World Health Organization.

 

3.                 
Global Access Commitments 

 

The following paragraphs are intended to ensure
satisfaction of the Charitable Purposes. In consideration of the Foundation Investment, the Company agrees to the following
(collectively “Global Access Commitments”) effective as of the Closing Date (as defined in the SPA):

 

(a)               
Supply Commitment.

 

(i)                
The Company will use reasonable and diligent efforts to achieve technical success in commercial scale production of AA and
AD for ACTs that meet applicable WHO standards.

 

(ii)              
In each calendar year during the Commitment Period commencing in 2017, the Company will fulfill in accordance with the Company’s
ordinary course of business all reasonable orders for AA or AD from Purchasers up to an aggregate maximum of 300 MT of AA and AD
combined, but the Foundation understands and agrees that the timing of the Company fulfilling such an order may be delayed if at
the time the Company’s resources are constrained as a result of fulfilling its commitments pursuant to this Letter Agreement
with respect to technology transfer or the deposit of Escrowed Materials and that a delay in fulfilling an order for such reasons
will not constitute a material breach of this Letter Agreement.

 

(b)              
Affordability.

 

(i)                
During the Commitment Period, the Company will supply the AA or AD to Purchasers at a price not to exceed COGS plus ten
percent (10%).

 

(ii)              
During the Commitment Period, the Company will include the following binding commitment, using language substantially similar
to the following, in each purchase and/or supply agreement with a Purchaser for the purchase of the Company’s AA or AD that
will be converted into artemisinin and included into ACTs:

 

“[Purchaser] agrees that it (i)
will sell artemisinin and/or ACTs produced using any of the AA or AD produced by the Company at a price that is affordable for
public sector purchasers of ACTs such as the Global Fund to Fight AIDS, TB and Malaria or the President’s Malaria Initiative
and (ii) will take into account any savings in the cost of its production resulting from the lower price of AA or AD produced by
the Company when setting the price of its artemisinin and/or ACTs.”

 

The Company will take reasonably necessary steps
to ensure that its Purchasers comply with such binding commitments. The Company and the Foundation acknowledge that the intent
of the foregoing provision is to try to ensure that any cost savings in the price of AA or AD

    	 	6	 

     

    

 

produced by the Company relative to AA or AD market prices as of
the date of this Letter Agreement will result in a lower cost of artemisinin and/or ACTs for end users, and the Company and the
Foundation will cooperate in good faith during the Commitment Period to modify these provisions as needed to best achieve this
objective.

 

(c)               
Covenant not to Sue Third Party AA or AD Producers under the Company’s Patents. If, prior to the Foundation’s
grant of a non-exclusive sublicense in subsection (d)(ii) below, a third party making, using, offering for sale, selling, or importing
AA or AD that is solely used to produce artemisinin for ACTs to treat malaria infringes or allegedly infringes a claim of a patent
or patent application owned or licensed by the Company that is necessary to make such AA or AD (other than any patents or patent
applications exclusively licensed or sublicensed to The Institute for OneWorld Health per the Amended and Restated Exclusive Development
and Commercialization Agreement dated January 11, 2008 (the “IOWH Agreement”)), the Company covenants to the
Foundation that it will not seek to enforce (whether via an injunction, a declaratory relief action, a claim for damages, or otherwise)
such patent or patent application against such third party’s making, using, offering for sale, selling, or importation of
such AA or AD. Such a third party will be considered a third-party beneficiary under this Agreement for the purpose of enjoying
the benefits of this subsection (c). For clarity, such covenant does not apply to a third party’s making, using, offering
for sale, selling, or importation of AA or AD that is not solely used to produce artemisinin for ACTs to treat malaria. In addition,
the Company has no obligation under this subsection (c) to provide, transfer, permit use of, license, disclose, or otherwise make
available to any third party any of the Company’s Strains, Know-How, or other Intellectual Property relevant to making, using,
offering for sale, selling, or importing AA or AD.

 

(d)              
Non-Exclusive License to the Foundation.

 

(i)                
License Grant. Effective at Closing (as defined in the SPA), for a one-time fee of Ten Thousand Dollars ($10,000),
the Company hereby grants the Foundation a worldwide, non-exclusive, perpetual, irrevocable, fully-paid up, royalty-free, sub-licensable
license under all Intellectual Property owned or licensed by the Company that is necessary to make, use, import, sell and offer
for sale AA or AD from the escrowed Strain (other than any patents or patent applications exclusively licensed or sublicensed to
The Institute for OneWorld Health per the IOWH Agreement) solely for the Foundation and its sublicensees to make, use, import,
sell, and offer for sale AA or AD from the escrowed Strain solely for the production of artemisinin for ACTs to treat malaria.

 

If requested in writing by the Foundation, the Company agrees to
cooperate with the Foundation in executing documents reflecting or recording the foregoing license.

 

(ii)              
Sublicensees. The Foundation shall have the right to grant sublicenses of the license granted in subsection (d)(i);
provided, however, with respect to a sublicense for the making of AA and AD (including access to and use of the escrowed Strain
and other Escrowed Materials described in subsection (d)(iii) below), the Foundation may grant a sublicense for the making of AA
or AD (and provide access to and use of the escrowed Strain and other Escrowed Materials) to only a sublicensee (1) who has executed
a written sublicense agreement with the Foundation that contains the provisions set forth in Appendix 3 attached hereto and (2)
for whom

 

    	 	7	 

     

    

the Company has provided its prior written consent
(not to be unreasonably withheld, conditioned or delayed) or who is listed by the parties on Appendix 4 attached hereto.

 

Each
sublicensee must be an entity or organization with a reputable record for safety, legal compliance, and corporate integrity.

 

(iii)            
Escrow of AA/AD Strain for the Foundation’s License. The Company shall, within the later of forty-five (45)
days of the date of this Letter Agreement and five (5) business days after the Closing Date (as defined in the SPA), deposit with
a mutually agreed third party escrow agent (the “Escrow Agent”), pursuant to an escrow agreement entered between
such Escrow Agent, the Company, and the Foundation: (1) the Strain that the Company is currently using to produce AA and AD and
(2) the Company’s current process, including a report (the “Technology Transfer Report”), which includes
the following elements: a description of the current production process, applicable standard operationg procedures (the “SOPs”),
in-process and final product specifications, analytical method development and validation reports, contact information and production
requirements for external CRO’s or CMO’s engaged by the Company to perform process steps in the production of AA and
AD, contact information for suppliers of critical reagents, and all additional materials and information
needed to produce AA and AD with such Strain (collectively (1) and (2), as updated from
time-to-time by the Company under the next paragraph, the “Escrowed Materials”).

 

The Company
shall, on or about every April 1 and October 1 and in addition within thirty (30) days of a one-time written request by the Foundation,
update the Escrowed Materials by replacing (1) the escrowed Strain with the Company’s then-most current, improved version
of the Strain used to produce AA and AD and (2) the Technology Transfer Report to produce AA and AD with such then-current Strain.
Upon the conclusion of the Company’s AA and AD Strain development program under this Letter Agreement, the Company will make
a final deposit of the final optimized AA and AD Strain with the Escrow Agent and a Technology Transfer Report for the optimized
Strain, after which deposit the Company’s obligations to update the Escrowed Materials shall terminate.

 

The Foundation
will have the right to request release of the Escrowed Materials from the Escrow Agent at any time following their deposit to any
entity that has a sublicensee under subsection d(ii) to make AA or AD. During the Commitment Period, upon release of the Escrowed
Materials to a sublicensee under subsection d(ii), the Company agrees to provide, commencing after sixty (60) days prior written
notice from the Foundation, reasonable Technical Assistance to such sublicensee to enable the sublicensee to make effective use
of the Escrowed Materials consistent with the license in subsection (d)(i). However, the parties agree that the Company is not
obligated to provide Technical Assistance to more than five (5) sublicensees, even if the Foundation has sublicensed more than
five (5) sublicensees under subsection d(ii). Due to the potential variances in sublicensees’ facilities, equipment, capabilities,
personnel, experience, locations, infrastructure, and/or operations, there is no guarantee of successful implementation or performance
of the Escrowed Materials at any sublicensee, even after the Technical Assistance.

 

Any dispute
between the parties regarding the deposit or release of the Escrowed Materials shall be resolved as provided in Section 21.

 

    	 	8	 

     

    

For clarity, the Escrowed Materials shall be used by the Foundation
and its sublicensees only pursuant to the license granted in subsection (d)(i) and the restrictions set forth in subsection (d)(i)
and (d)(ii) above, and such disclosure or release is not intended to grant any other rights of use, express or implied.

 

(e)               
Treatment of Additional Target Diseases. The parties acknowledge that in addition to the use of artemisinin to produce
ACTs to treat malaria, now or in the future it may be possible for artemisinin to be used for the treatment of other Target Diseases.
The Company agrees that during the Commitment Period, if the Foundation so requests in writing to the Company, (i) the license
granted in Section 3(d)(i) of this Letter Agreement (including any sublicense thereof) will also allow the Foundation and its sublicensees
to make, use, import, sell, and offer for sale AA or AD from the escrowed Strain for the production of artemisinin for use in the
treatment of any or all of the Target Diseases and (ii) the covenant not to sue in Section 3(c) will also apply to the making,
using, offering for sale, selling, or importing of AA or AD that is used for the production of artemisinin for use in the treatment
of any or all of the Target Diseases.

 

4.                 
Third Party Costs.

 

Except as otherwise provided in this Letter
Agreement, the Company shall be responsible for all costs associated with its technology and Intellectual Property owned, controlled
or licensed-in. The Company shall use reasonable and diligent efforts to ensure that any Intellectual Property and technology it
owns, controls or in-licenses is available for potential sublicensing to the Foundation and other third parties consistent with
the terms of this Letter Agreement. For the avoidance of doubt, the obligations under this paragraph shall not require the Company
to secure rights to any third party Intellectual Property at the Company’s expense. Consequently, if a third party licensor
to the Company requires any fees, milestones, royalties, and/or other compensation for the Company to sublicense such third party’s
Intellectual Property to the Foundation or its sublicensees under Section 3(d)(i), the Foundation or its sublicensees must pay
all such amounts and comply with the terms of Company’s license agreement with such third party.

 

5.                 
Obligations in the Event of Acquisition; Preservation of Global Access Commitments.

 

In the event the Company or the Company assets
necessary to perform the Company’s obligations under the Transaction Documents are transferred to, sold or acquired by a
third party, including as a result of a Change in Control (any such transfer, sale or acquisition, including a Change in Control,
is referred to herein as a “Transfer”), the Company will ensure all of the Company’s obligations hereunder
are assumed by the purchaser, transferee, acquirer or successor in a written agreement reasonably acceptable to the Foundation.
Excluding (i) the Company’s non-compete covenant in Section 7.6(a) of the IOWH Agreement and (ii) the licenses and sublicenses
granted by the Company to OneWorld Health per the IOWA Agreement, the Company will not grant to a third party any rights or enter
into any arrangements that would prohibit, prevent or otherwise restrict the Company or any purchaser, transferee, acquirer, or
successor of Company assets or the Company from fulfilling the Global Access Commitments and the Company’s other obligations
under the Transaction Documents. For clarity, notwithstanding anything to the contrary in the Transaction Documents, the Foundation’s
rights hereunder which exist on the date of a Transfer shall not be terminated by such Transfer.

 

    	 	9	 

     

    

6.                 
Withdrawal Rights.

 

(a)               
A “Charitability Default” will occur if the Company either (i) fails to comply with the restrictions
in Sections 1(c) and 9 of this Letter Agreement on the use of funds from the Foundation Investment, (ii) fails to comply with the
other related U.S. legal obligations set forth in this Letter Agreement, including the requirements set forth in Sections 7, 8,
11, and 11 below, or (iii) is in material breach of the Global Access Commitments (for the avoidance of doubt the parties agree
that a breach of the Global Access Commitments that tax counsel selected by the Foundation determines is more likely than not to
result in the Foundation Investment failing to qualify as a “program related investment” under the Code will constitute
a material breach of the Global Access Commitments). Each party agrees to promptly notify the other party in writing if it becomes
aware of any Charitability Default. Notwithstanding anything in this Agreement to the contrary, the Foundation will not lose any
rights or remedies solely as a result of a failure to notify the Company after it becomes aware of a Charitability Default.

 

(b)              
If the Company commits a Charitability Default and fails to remedy it within ninety (90) days of receipt of the above described
notice, then, in addition to all other rights and remedies available at law or in equity, at any time following the cure period
set forth above in this Section 6(b), the Foundation will have the right to request that the Company proceed with one of the following
(the “Withdrawal Rights”):

 

(i)                
redeem all of the then-held Foundation Stock at a price per share equal to the greater of (x) the Minimum Purchase Price
or (y) the Fair Market Value, provided that such redemption shall be made only to the extent permitted by applicable law concerning
distributions to holders of equity interests,

 

(ii)              
facilitate the purchase of the then-held Foundation Stock by a third party at a price per share equal to the greater of
(x) the Minimum Purchase Price or (y) the Fair Market Value in a transaction that complies with applicable law, or

 

(iii)            
solely in the event the Common Stock is not Freely Tradable at the time, the Company may elect to register the resale of
the then-held Foundation Stock on an effective registration statement filed under the Securities Act with the SEC and keep the
registration statement continuously effective under the Securities Act until the earlier of (x) the date all of the Foundation
Stock has been sold or (y) the date that is 2 years following the effective date of the registration statement. 

 

If the Company elects to satisfy the Withdrawal
Right pursuant to Section 6(b)(iii) and the Foundation receives less than the Minimum Purchase Price per share for any of the Foundation
Stock sold, then the Company will pay the Foundation as soon as practicable the difference between the price received by the Foundation
and the Minimum Purchase Price.

 

(c)               
If the Company is unable to redeem all of the then-held Foundation Stock under Section 6(b)(i) because it is prohibited
from doing so under applicable law concerning distributions to holders of equity interests, and the Company is not able to provide
the Withdrawal Right pursuant to Section 6(b)(ii) or 6(b)(iii), then the Company shall redeem as much of the Foundation Stock as
is legally permissible and continuously use its best efforts to effect the Withdrawal Rights,

 

    	 	10	 

     

    

consistent with applicable law, until such time
as the Foundation and its Affiliates no longer hold any Foundation Stock. 

 

(d)              
Except as otherwise provided in the Transaction Documents, the Company’s obligations and the Foundation’s rights
under the Transaction Documents, including the Global Access Commitments, will survive following the Foundation’s complete
divestiture, whether via Withdrawal Rights and/or other sale or transfer, of the Foundation Stock.

 

(e)               
The Company shall pay all fees and expenses incident to the performance of or compliance with the Foundation’s exercise
of its Withdrawal Rights.

 

7.                 
Required Reporting; Audit Rights

 

In addition to any and all reports required
to be delivered to the Foundation under Section 8 below, the Company shall furnish, or cause to be furnished, to the Foundation
the following reports and certifications:

 

(a)               
Within ninety (90) days after the end of each of the Company’s fiscal years during which the Foundation owns any Foundation
Stock, a certificate from the Company signed by an officer or director of the Company and substantially in the form attached to
this Letter Agreement as Appendix 1, certifying that the requirements of the Foundation Investment set forth in this Letter Agreement
were met during the immediately preceding fiscal year, describing the use of the proceeds of the Foundation Investment and evaluating
the Company’s progress toward achieving the Global Access Commitments;

 

(b)              
Within ninety (90) days after the end of the Company’s fiscal year during which the Foundation ceases to own any Foundation
Stock, a certificate from the Company signed by an officer or director of the Company and substantially in the form attached to
this Letter Agreement as Appendix 2, certifying that the requirements of the Foundation Investment set forth in this Letter Agreement
were met during the time that the Foundation held any Foundation Stock, describing the use of the proceeds of the Foundation Investment
and evaluating the Company’s progress toward achieving the Global Access Commitments;

 

(c)               
Any other information respecting the operations, activities and financial condition of the Company as the Foundation may
from time to time reasonably request to discharge any expenditure responsibility, within the meaning of Sections 4945(d)(4) and
4945(h) of the Code, of the Foundation with respect to the Foundation Investment, and to otherwise monitor the charitable benefits
intended to be served by the Foundation Investment. The Foundation will reimburse the Company for any reasonable third-party expenses
incurred by the Company in order to prepare any information the Company is required to prepare solely as a result of this Section
7(c); and

 

(d)              
During the two (2) years following the date of this Letter Agreement, within thirty (30) days after the end of each of the
Company’s fiscal quarters during which the Foundation owns any Foundation Stock, a financial report showing the Company’s
projected income statement, cash

 

    	 	11	 

     

    

flow statement and balance sheet for each fiscal
quarter remaining in the current fiscal year and the following fiscal year.

 

(e)               
Full and complete financial reports of the type ordinarily required by commercial investors under similar circumstances
to the extent required pursuant to Treasury Regulation 53.4945-5(b)(4) , provided that as long as the Company is a reporting company
under the Exchange Act, the timely filing of quarterly, annual and current reports pursuant to section 13 or 15(d) of the Exchange
Act and all other required filings with the SEC shall be deemed to satisfy the financial reporting obligations in this Section
7(d).

 

(f)               
The following programmatic reports:

 

(i)                
Progress report on process development to scale-up and mass produce AA and AD to the necessary quality standards including
the resulting COGS and new Strain development. Such report will be provided quarterly for the first 12 months after the date of
this Letter Agreement, semi-annually for the next 12 months and annually thereafter.

 

(ii)              
Annual report on sales of AA and AD, including the volume, price, Purchasers and COGS.

 

(g)              
 The Company will maintain adequate accounting records and copies of any reports submitted to the Foundation related to
sales of AA and AD to Purchasers. The Company will retain such records and reports for 4 years after the Foundation’s funds
are fully spent and will make such records and reports available, pursuant to Section 8 below, to enable the Foundation to monitor
and evaluate how the Foundation’s funds have been used.

 

8.                 
Access to Records

 

The Company shall maintain books and records
adequate to provide such information as is necessary to comply with Treasury Regulations section 53.4945-5(b)(4), as amended from
time to time. The Company shall provide the Foundation access to such books and records at reasonable times for a period
beginning on the Closing Date (as defined in the SPA) and ending four years after the date on which the Foundation no longer holds
any Foundation Stock. For the avoidance of doubt, the Foundation’s access shall not be dependent upon the Foundation’s
percentage ownership in the Company.

 

Without limiting the generality of the foregoing
paragraph, the Company agrees to permit employees or agents of the Foundation, all of whom are bound by written confidentiality
obligations or policies substantially similar to the Foundation’s obligations under the CDA, at any reasonable time and upon
reasonable prior notice, during normal business hours, to examine or audit the Company’s relevant books and accounts of record
and to make copies and memoranda of the same, in each case at the Foundation’s expense to audit the Company’s compliance
with the use of the Foundation Investment, the Global Access Commitments (including COGS and total cost of ownership) and the reporting
requirements set forth herein; provided that the Foundation will not conduct such an examination or audit more frequently than
once per calendar year unless required due to any audit, request or inquiry of the Foundation by the Internal Revenue Service or
because the Company previously materially failed such an annual audit. If the Company maintains any relevant records (including
computer generated records and computer software programs for

 

    	 	12	 

     

    

the generation of such records) in the possession
of a third party, the Company, upon request of the Foundation, will notify such party to permit the Foundation free access to such
records at all reasonable times and to provide the Foundation with copies of any records it may reasonably request in connection
with such audit, request or inquiry, all at the Foundation’s expense. All such information provided or disclosed hereunder
that constitutes Proprietary Information as defined in the CDA is subject to the CDA.

 

9.                 
Prohibited Uses.

 

The Company shall not expend any proceeds of
the Foundation Investment to carry on propaganda or otherwise to attempt to influence legislation, to influence the outcome of
any specific public election or to carry on, directly or indirectly, any voter registration drive, or to participate or intervene
in any political campaign on behalf of or in opposition to any candidate for public office within the meaning of Section 4945(d)
of the Code. The proceeds of the Foundation Investment shall not (a) be earmarked to be used for any activity, appearance or communication
associated with the activities described in the foregoing sentence, nor (b) be intended for the direct benefit of, and will not
benefit, any person having a personal or private interest in the Foundation, including descendants of the founders of the Foundation,
or persons related to or controlled by, directly or indirectly, such private interests.

 

For the avoidance of doubt, the Company will
not use the funds received from the Foundation to pay a dividend or redeem shares.

 

10.             
Disqualified Person. 

 

To the knowledge of each of the Foundation and
the Company: (a) the Company is not a “disqualified person” with respect to the Foundation (as the term “disqualified
person” is defined in Section 4946(a) of the Code), (b) no disqualified person with respect to the Foundation owns more than
five (5) percent of the Company’s shares, and (c) the Foundation does not, and one or more disqualified persons with respect
to the Foundation do not, directly or indirectly, control the Company. With respect to “knowledge” of the Company,
such representation is based solely on a review of the SEC filings made by third parties as required under the US securities laws
and the stock records of its transfer agent as of the most recent practicable date prior to entry into this Letter Agreement.

 

11.             
Anti-Terrorism.

 

The Company will not use the Foundation Investment,
directly or indirectly, in support of activities (a) prohibited by U.S. laws related to combatting terrorism; (b) with persons
on the List of Specially Designated Nationals (www.treasury.gov/sdn) or entities owned or controlled by such persons; or (c) with
countries against which the U.S. maintains a comprehensive or targeted sanctions embargo (currently, Cuba, Iran, (North) Sudan,
Syria, North Korea, Russia and Ukraine), unless such activities are fully authorized by the U.S. government under applicable law
and specifically approved by the Foundation in its sole discretion.

    	 	13	 

     

    

 

12.             
Anti-Corruption and Anti-Bribery.

 

The Company will not offer or provide money,
gifts, or any other things of value directly or indirectly to anyone in order to improperly influence any act or decision relating
to the Foundation or any activities contemplated by the Transaction Documents or the Company’s organizational documents (e.g.,
certificate of incorporation), including by assisting any party to secure an unlawful advantage. Training and information on compliance
with these requirements are available at www.learnfoundationlaw.org.

13.             
Public Reports; Use of Name.

 

The Foundation may include information on this
investment in its periodic public reports and may make the investment public at any time on its web page and as part of press releases,
public reports, speeches, newsletters and other public documents, and to the extent required by applicable law or regulation. Any
announcement of the Foundation Investment by the Company or on behalf of the Company by its representatives, directors, stockholders
and agents, will require the Foundation’s prior written approval.  Such parties shall also obtain the Foundation’s
prior written approval for any other use of the Foundation’s name or logo in any respect; provided, however, that the Company
may use the Foundation’s name for any uses that have been pre-approved in writing by the Foundation.  Notwithstanding
the foregoing, the Foundation’s name and logo will not be used by any party in any manner to market, sell or otherwise promote
the Company, its products, services and/or business. Nothing in this Section 13 prohibits the Company from disclosing the Transaction
Documents, the transactions contemplated therein, or the Foundation’s identity and participation to the extent such disclosure
is required by applicable laws, regulations, or stock exchange requirements.

 

14.             
Indemnification.

 

(a)               
Company’s Obligation. The Company will indemnify, hold harmless, and defend the Foundation and its co-chairs, trustees,
directors, officers, employees, agents, and representatives (collectively, the “Indemnitees”) from and against
any and all third party causes of action, claims, suits, legal proceedings, judgments, settlements, damages, penalties, losses,
liabilities and costs (including reasonable attorneys’ fees and costs) (each a “Claim”) finally awarded
to such third party by a court of competent jurisdiction against any of the Indemnitees or agreed to as part of a monetary settlement
of the Claim to the extent arising out of or relating to bodily injury, death or property damage caused by the Company’s
making, using, selling, offering for sale, and importation of AA and AD or the Company’s infringement or misappropriation
of a third party’s Intellectual Property.

 

THE COMPANY ACKNOWLEDGES AND AGREES THAT THE FOUNDATION’S
ROLE UNDER THE TRANSACTION DOCUMENTS IS STRICTLY TO PROVIDE CHARITABLE FUNDING THROUGH THE FOUNDATION INVESTMENT AND THAT THE FOUNDATION
DOES NOT HAVE RESPONSIBILITY FOR, OR CONTROL OVER, THE

 

    	 	14	 

     

    

DESIGN, DEVELOPMENT, PRODUCTION, MANUFACTURE,
SALE, DISTRIBUTION, EXPORT, OWNERSHIP, POSSESSION OR USE OF ANY COMPANY PRODUCTS.

 

(b)              
Process. The Foundation will give the Company prompt written notice of any Claim subject to indemnification; provided that
the Foundation’s failure to promptly notify the Company will not affect the Company’s indemnification obligations except
to the extent that the Foundation’s delay prejudices the Company’s ability to defend the Claim. The Company will have
sole control over the defense and settlement of each and every Claim, with counsel of its own choosing which is reasonably acceptable
to the Foundation; provided that the Company conducts the defense actively and diligently at the sole cost and expense of the Company
and provided further that the Company will not enter into any settlement that adversely affects any Indemnitee without the applicable
Indemnitee’s prior written consent, such consent not to be unreasonably withheld, conditioned or delayed. The Foundation
will provide the Company, upon request, with reasonable cooperation in connection with the defense and settlement of the Claim.
Subject to the Company’s rights above to control the defense and settlement of Claims, the Foundation and any Indemnitee
may, at its own expense, employ separate counsel to monitor and participate in the defense of any Claim under this Section 14.
The Company shall not have any liability or obligations with respect to any Claim under this Section 14 to the extent such Claim
results from an Indemnitee’s fraud, negligence, gross negligence or willful misconduct.

 

(c)               
Disclaimer. THE PARTIES WILL NOT BE LIABLE TO EACH OTHER FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, OR SPECIAL
DAMAGES (INCLUDING LOST REVENUES, LOST SAVINGS, OR LOST PROFITS SUFFERED BY SUCH OTHER PARTY) SUFFERED BY SUCH OTHER PARTY ARISING
UNDER OR IN CONNECTION WITH THIS LETTER AGREEMENT, REGARDLESS OF THE FORM OF ACTION, WHETHER IN CONTRACT OR TORT, INCLUDING NEGLIGENCE
OF ANY KIND WHETHER ACTIVE OR PASSIVE, AND REGARDLESS OF WHETHER THE PARTY KNEW OF THE POSSIBILITY THAT SUCH DAMAGES COULD RESULT;
provided that to the extent an Indemnitee is entitled to be indemnified hereunder for Claims of third parties and such third party
has been awarded indirect, incidental, consequential, reliance, or special damages (including lost revenues, lost savings, or lost
profits), the Company’s indemnification obligations to the Indemnitee shall extend to and include such third party’s
indirect, incidental, consequential, reliance, or special damages (including lost revenues, lost savings, or lost profits). 
The parties further agree that under no circumstances will any party be liable to the other party (or to any Indemnitee) more than
once for the same losses arising under or in connection with this Letter Agreement.

 

15.             
Assignment

 

This Letter Agreement may not be assigned by
either party without the prior written consent of the other party; provided, that this Letter Agreement may be assigned
by the Foundation to an Affiliate. The Foundation will notify the Company of any such assignment, including the identity of the
assignee, in a timely manner. For the avoidance of doubt, if the Foundation transfers the Foundation Stock to an Affiliate, the
Foundation may assign to any such transferee all of its rights under this Letter Agreement attached to such Foundation Stock, including
the Withdrawal Rights. This Letter Agreement and all provisions thereof shall be binding upon, inure to the benefit of, and are
enforceable by the parties hereto and their respective successors and permitted assigns.

 

    	 	15	 

     

    

16.             
Entire Agreement; Modification

 

This Letter Agreement and the other Transaction
Documents, including all exhibits hereto and thereto, set forth all the covenants, promises, agreements, warranties, representations,
conditions and understandings between the parties with respect to the subject matter of the Transaction Documents, and supersede
and terminate all prior agreements, negotiation and understandings between the parties, whether oral or written, with respect to
such subject matter. No subsequent alteration, modification, amendment, change or addition to this Letter Agreement shall be binding
upon the parties unless reduced to writing and signed by the respective authorized officers of the parties. In the event of a conflict
between the terms of this Letter Agreement and the terms of any other Transaction Document, the terms of this Letter Agreement
shall control.

 

17.             
Authority

 

Each of the parties covenants, represents and
warrants that it had all authority necessary to execute this Letter Agreement and that, on execution, this Letter Agreement will
be fully binding and enforceable in accordance with its terms, and that no other consents or approvals of any other person or third
parties (including, with regard to the Company, Hercules Technology Growth Capital, Inc.) are required or necessary for this Letter
Agreement to be so binding.

 

Except for the Company’s non-compete covenant
in Section 7.6(a) of the IOWH Agreement, the execution, delivery and performance by the Company of this Letter Agreement and the
consummation by the Company of the transactions contemplated hereby do not and will not (a) conflict with or violate any provisions
of the Company’s certificate of incorporation or bylaws or otherwise result in a violation of the organizational documents
of the Company, (b) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become
a default) under any Material Contract, or (c) result in a violation of any law, rule, regulation, order, judgment, injunction,
decree or other restriction of any court or governmental authority to which the Company is subject, or by which any property or
asset of the Company is bound or affected, except in the case of clause (c) such as would not, individually or in the aggregate,
be reasonably expected to have a material adverse effect on the Company or its business.

 

EXCEPT AS EXPRESSLY SET FORTH IN THIS LETTER AGREEMENT,
NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY WARRANTY, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE
OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING
ANY WARRANTY OF QUALITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR USE OR PURPOSE, OR SAFETY, AND ANY WARRANTY AS TO THE NON-INFRINGEMENT
OF ANY THIRD PARTY’S INTELLECTUAL PROPERTY RIGHTS THROUGH THE PRACTICE OF ANY INTELLECTUAL PROPERTY LICENSED HEREUNDER.

    	 	16	 

     

    

 

18.             
Charitability Opinion

 

As a condition to making the Foundation Investment,
the Foundation shall have obtained a written legal opinion from tax counsel (to be provided at the Foundation’s expense),
that the Foundation Investment will qualify as a program-related investment under the Code.

 

19.             
Headings, etc.

 

Section headings are not to be considered part
of this Letter Agreement, are included solely for convenience, are not intended to be full or accurate descriptions of the content
thereof and shall not affect the construction hereof. The words “include,” “includes” and “including”
used in this Letter Agreement shall be deemed to be followed by the words “without limitation.”

 

20.             
Governing Law

 

This Letter Agreement shall be governed by the
laws of the State of Washington, excluding its conflicts of laws provisions.

 

21.             
Dispute Resolution

 

The parties will resolve any dispute, controversy
or claim arising out of or relating to this Letter Agreement, or the breach, termination or invalidity hereof (“Dispute”)
in accordance with this Section 21. If a Dispute arises, the parties will each appoint a designated representative whose task it
will be to meet for the purpose of endeavoring to resolve such Dispute. The designated representatives shall meet as often as the
parties reasonably deem necessary to discuss the problem in an effort to resolve the Dispute without the necessity of any formal
proceeding. If such representatives are unable to resolve the Dispute within twenty (20) business days after the Dispute is submitted
to them, the Dispute shall be immediately referred by written notice to an executive officer of each of the parties.

 

If such executive officers are unable to resolve
such Dispute within ten (10) business days after the Dispute is submitted to them and a party wishes to pursue the Dispute further,
each such Dispute shall be finally resolved by binding arbitration in accordance with the rules of the American Arbitration Association
(“AAA”), and judgment on the arbitration award may be entered in any court having jurisdiction thereof. The
arbitration shall be conducted in English by a panel of three (3) persons experienced in the biotechnology business, as follows:
within thirty (30) days after initiation of arbitration, each party shall select one (1) person to act as arbitrator and the two
party-selected arbitrators shall select a third arbitrator within thirty (30) days of their appointment. If the arbitrators selected
by the parties are unable or fail to agree upon the third arbitrator in the established term, the third arbitrator shall be appointed
by the AAA. The place of arbitration shall be Seattle, WA or a place otherwise mutually agreeable to the parties. Either party
may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered or the controversy is otherwise
resolved. Unless otherwise agreed by the parties, any arbitration award will be issued no later than six (6) months after the conclusion
of the arbitration. It is expressly understood and agreed by the parties that the rulings and award of the tribunal shall be conclusive
on the parties, their successors and permitted assigns. Judgment on the award rendered by the tribunal may be entered in any court
having jurisdiction thereof. Either party also may, without waiving any remedy under this Letter Agreement, seek from any court
having jurisdiction any injunctive or

 

    	 	17	 

     

    

provisional relief necessary to protect the rights
or property of that party pending the arbitration award. The arbitrators shall have no authority to award punitive or any other
type of damages or relief prohibited or excluded elsewhere under this Letter Agreement. Each party will bear its own costs and
expenses and attorneys’ fees in an arbitration, but the cost of any arbitration (including the fees and expenses of the arbitrators)
shall be borne by the parties in inverse proportion as they may prevail on matters resolved by the arbitrators, which proportionate
allocations shall also be determined by the arbitrators at the time the determination of the arbitrators is rendered on the merits
of the matters submitted. Except to the extent permitted under the CDA, neither a party nor an arbitrator may disclose the existence,
content, or results of an arbitration without the prior written consent of both parties.

 

22.             
Counterparts.

 

This Letter Agreement may be executed in one
or more counterparts, including by signatures delivered by facsimile or pdfs, each of which shall be deemed an original, but all
of which shall be deemed to be and constitute one and the same instrument.

 

[Signature Page Follows]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	18	 

     

    

 

IN WITNESS WHEREOF, the parties have caused this
Letter Agreement to be executed on April 8, 2016.

 

	Amyris, Inc.	 	Bill & Melinda Gates Foundation
	 	 	 
	 	 	 	 	 	 
	By:	/s/ Nicholas Khadder	 	By:	/s/ Jim Bromley	 
	 	 	 	 	 	 
	Name:	Nicholas Khadder	 	Name:	Jim Bromley	 
	 	 	 	 	 	 
	Title:	Corporate Secretary &	 	Title:	CFO	 
	 	General Counsel	 	 	 	 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     

     

    

 

Appendix 1

 

[OFFICER’S/DIRECTOR’S] CERTIFICATE

 

AMYRIS, INC.

 

[DATE]

 

This certificate is being delivered by Amyris, Inc., a Delaware corporation
(the “Company”), pursuant to Section 7(a) of the Letter Agreement between the Company and the Bill &
Melinda Gates Foundation dated as of April 8, 2016 (the “Letter Agreement”). Capitalized terms used but not
otherwise defined herein shall have the meanings ascribed to them in the Letter Agreement.

 

The Company certifies as follows:

 

1.                 
During the fiscal year ended [DATE], the Company met the requirements of the Foundation Investment as set forth in the Letter Agreement
that were required to be complied with or performed by the Company during such time period.

 

2.                 
Attached as Exhibit A to this certificate is a description of the Company’s use of proceeds of the Foundation Investment
during the fiscal year ended [DATE].

 

3.                 
Attached as Exhibit B to this certificate is the Company’s evaluation of the Company’s progress with respect
to the process development activities set forth in Section 1(c) of the Letter Agreement and the Global Access Commitments set forth
in the Letter Agreement during the fiscal year ended [DATE].

 

IN WITNESS WHEREOF, the undersigned has executed this certificate
and has caused this certificate to be delivered on the date first above written.

 

 

	 	Amyris, Inc.	 
	 	 	 	 
	 	By:	 	 
	 	 	Name:	 
	 	 	Title:	 

 

 

 

 

 

 

     

     

    

 

Appendix 2

 

[OFFICER’S/DIRECTOR’S] CERTIFICATE

 

AMYRIS, INC.

 

[DATE]

 

This certificate is being delivered by Amyris, Inc., a Delaware corporation
(the “Company”), pursuant to Section 7(b) of the Letter Agreement between the Company and the Bill &
Melinda Gates Foundation dated as of April 8, 2016 (the “Letter Agreement”). Capitalized terms used but not
otherwise defined herein shall have the meanings ascribed to them in the Letter Agreement.

 

The Company certifies as follows:

 

1.                 
During the term of the Foundation Investment, the Company met the requirements of the Foundation Investment as set forth in the
Letter Agreement that were required to be complied with or performed by the Company during such time period.

 

2.                 
Attached as Exhibit A to this certificate is a description of the Company’s use of proceeds of the Foundation Investment
during the term of the Foundation Investment.

 

3.                 
Attached as Exhibit B to this certificate is the Company’s evaluation of the Company’s progress with respect
to the process development activities set forth in Section 1(c) of the Letter Agreement and the Global Access Commitments set forth
in the Letter Agreement during the term of the Foundation Investment.

 

IN WITNESS WHEREOF, the undersigned has executed this certificate
and has caused this certificate to be delivered on the date first above written.

 

 

	 	Amyris, Inc.	 
	 	 	 	 
	 	By:	 	 
	 	 	Name:	 
	 	 	Title:	 

 

 

 

 

 

     

     

    

Appendix 3

 

TERMS OF ANY SUBLICENSE AGREEMENT TO MAKE AA OR AD

 

1.Sublicensee will not use the released escrowed Strain except
to make AA and AD, and such AA and AD will be used, imported, offered for sale, and sold only for the production of artemisinin
for ACTs to treat malaria.

 

2.Sublicensee will covenant not to reverse engineer the released
escrowed Strain, not to engineer or genetically modify such Strain, and not to distribute, disclose or transfer such Strain or
any related Intellectual Property to any third party unless expressly agreed in writing by the Company, in its sole discretion.

 

3.Sublicensee will agree to (i) hold in strict confidence and
take all reasonable precautions to protect the Escrowed Materials (including the Strain) and any other Proprietary Information
(as defined in the CDA) of the Company that it obtains and (ii) not divulge any of such information or any information derived
therefrom to any employee who does not have a need to know for the sublicensee to exercise its sublicense rights or to any third
party.

 

4.Each sublicensee will represent and warrant that its manufacture
and supply of AA and AD will be conducted in accordance with applicable laws, rules and regulations.

 

5.The sublicensee’s sublicense and use and possession
of the Escrowed Materials (including the Strain) will terminate immediately upon sublicensee’s breach of the sublicense agreement.
Upon termination, the sublicensee will immediately destroy all of the Strain in its possession and certify to such destruction.

 

6.At least once per quarter, the Company will have the right,
upon reasonable prior notice and during normal business hours, to inspect the sublicensee’s facilities at which the AA and
AD is manufactured from the released escrowed Strain.

 

7.The Company will have the right, upon reasonable prior notice
and during normal business hours, to have a representative present from time-to-time during a sublicensee’s manufacture of
the AA and AD from the released escrowed Strain.

 

8.The Company will be named as a third party beneficiary of
the sublicense agreement between the Foundation and the sublicensee, and as between the Foundation and the Company, the Company
will have the primary right, but not obligation, to pursue actions against the sublicensee to protect the released escrowed Strain
and related Intellectual Property vis a vis the sublicensee.

 

9.Each sublicensee will, per reasonable and customary obligations,
agree to indemnify the Company for sublicensee’s actions under the sublicense.

 

10.Each sublicensee will obtain and maintain insurance coverage
with a reputable carrier at amounts commercially reasonable for its activities and commitments under its sublicense.

 

 

 

     

     

    

Appendix 4

 

FOUNDATION’S INITIAL SUBLICENSEES TO MAKE AA OR AD

 

 

 

Anthem BioSciences

 

Apello, a division of Hengdian Group Kangyu Pharmaceutical Co.,
Ltd.

 

Biocon Ltd.

 

Celltrion Inc.

 

Cipla Ltd.

 

Concord Biotech Ltd.

 

Fosun Pharma

 

Green Cross Corporation

 

Huvepharma NV

 

Ipca Laboratories

 

LG Life Science Ltd.

 

Pfizer Inc.

 

Shanghai Aurisco Industry Co. Ltd. / Zhejiang Tiantai Aursico
Pharma, Co., Ltd.

 

Sterling Pharmaceutical Services

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}]]